https://trial.medpath.com/news/coya-therapeutics-coya-303-demonstrates-anti-inflammatory-effects-in-preclinical-alzheimer-s-model 2025-07-25T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-coya-303-demonstrates-anti-inflammatory-effects-in-preclinical-alzheimer-s-model 2025-07-25T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-advances-multi-platform-pipeline-with-novel-arm-technology-for-autoimmune-diseases 2025-07-25T01:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janux-therapeutics-advances-multi-platform-pipeline-with-novel-arm-technology-for-autoimmune-diseases 2025-07-25T01:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/nextcure-s-anti-siglec-15-antibody-nc605-shows-promise-for-osteogenesis-imperfecta-treatment-in-preclinical-study 2025-07-25T01:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextcure-s-anti-siglec-15-antibody-nc605-shows-promise-for-osteogenesis-imperfecta-treatment-in-preclinical-study 2025-07-25T01:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-s-brensocatib-wins-fda-approval-as-first-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-07-25T01:25:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-s-brensocatib-wins-fda-approval-as-first-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-07-25T01:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/pedal-study-demonstrates-prospera-kidney-test-accurately-predicts-long-term-outcomes-after-transplant-rejection 2025-07-25T01:25:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pedal-study-demonstrates-prospera-kidney-test-accurately-predicts-long-term-outcomes-after-transplant-rejection 2025-07-25T01:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/hydroxychloroquine-shows-promise-for-kidney-protection-in-primary-glomerular-disease-and-lupus-nephritis 2025-07-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydroxychloroquine-shows-promise-for-kidney-protection-in-primary-glomerular-disease-and-lupus-nephritis 2025-07-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iran-israel-conflict-disrupts-global-clinical-trial-landscape-as-india-overtakes-iran-in-q2-2025 2025-07-24T21:29:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iran-israel-conflict-disrupts-global-clinical-trial-landscape-as-india-overtakes-iran-in-q2-2025 2025-07-24T21:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/stevanato-group-secures-eur200-million-financing-to-expand-biologics-manufacturing-capacity 2025-07-24T21:29:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stevanato-group-secures-eur200-million-financing-to-expand-biologics-manufacturing-capacity 2025-07-24T21:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-xmab30819-shows-promise-in-advanced-clear-cell-renal-cell-carcinoma 2025-07-24T21:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bispecific-antibody-xmab30819-shows-promise-in-advanced-clear-cell-renal-cell-carcinoma 2025-07-24T21:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-initiates-phase-clinical-trial-for-bay3018250-in-deep-vein-thrombosis-treatment 2025-07-24T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-initiates-phase-clinical-trial-for-bay3018250-in-deep-vein-thrombosis-treatment 2025-07-24T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-seeks-japan-pmda-approval-for-cardiamp-cell-therapy-in-heart-failure-treatment 2025-07-24T21:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocardia-seeks-japan-pmda-approval-for-cardiamp-cell-therapy-in-heart-failure-treatment 2025-07-24T21:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/roche-discontinues-obesity-drug-ct-173-from-2-7b-carmot-acquisition-citing-lack-of-competitiveness 2025-07-24T21:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-discontinues-obesity-drug-ct-173-from-2-7b-carmot-acquisition-citing-lack-of-competitiveness 2025-07-24T21:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/gate-bioscience-partners-with-lilly-in-856-million-deal-to-develop-novel-molecular-gate-therapeutics 2025-07-24T21:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gate-bioscience-partners-with-lilly-in-856-million-deal-to-develop-novel-molecular-gate-therapeutics 2025-07-24T21:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/gnt-pharma-advances-first-in-class-dual-action-stroke-therapy-nelonemdaz-to-global-phase-3-trials 2025-07-24T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gnt-pharma-advances-first-in-class-dual-action-stroke-therapy-nelonemdaz-to-global-phase-3-trials 2025-07-24T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/cdx-diagnostics-receives-fda-breakthrough-device-designation-for-ai-powered-wats3d-esophageal-cancer-diagnostic-system 2025-07-24T21:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdx-diagnostics-receives-fda-breakthrough-device-designation-for-ai-powered-wats3d-esophageal-cancer-diagnostic-system 2025-07-24T21:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/tcg-labs-soleil-raises-400m-to-build-single-asset-biotech-startups-for-strategic-partnerships 2025-07-24T21:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tcg-labs-soleil-raises-400m-to-build-single-asset-biotech-startups-for-strategic-partnerships 2025-07-24T21:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/medcomms-experts-acquires-nexgen-healthcare-communications-to-expand-global-medical-communications-platform 2025-07-24T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medcomms-experts-acquires-nexgen-healthcare-communications-to-expand-global-medical-communications-platform 2025-07-24T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-s-pda-002-shows-promise-in-phase-2-trial-for-diabetic-foot-ulcers-with-peripheral-artery-disease 2025-07-24T17:44:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celularity-s-pda-002-shows-promise-in-phase-2-trial-for-diabetic-foot-ulcers-with-peripheral-artery-disease 2025-07-24T17:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-s-kb304-gene-therapy-achieves-100-response-rate-in-phase-1-decollete-wrinkle-trial 2025-07-24T17:41:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/krystal-biotech-s-kb304-gene-therapy-achieves-100-response-rate-in-phase-1-decollete-wrinkle-trial 2025-07-24T17:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-to-present-phase-2-darovasertib-data-for-uveal-melanoma-at-esmo-2025 2025-07-24T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-to-present-phase-2-darovasertib-data-for-uveal-melanoma-at-esmo-2025 2025-07-24T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/roche-explores-direct-to-consumer-drug-sales-model-to-reduce-us-patient-costs 2025-07-24T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-explores-direct-to-consumer-drug-sales-model-to-reduce-us-patient-costs 2025-07-24T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-advance-novel-treatments-for-androgenetic-alopecia-as-researchers-target-30-year-treatment-gap 2025-07-24T17:41:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trials-advance-novel-treatments-for-androgenetic-alopecia-as-researchers-target-30-year-treatment-gap 2025-07-24T17:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/sanner-opens-first-u-s-manufacturing-facility-in-north-carolina-expanding-global-cdmo-operations 2025-07-24T17:39:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanner-opens-first-u-s-manufacturing-facility-in-north-carolina-expanding-global-cdmo-operations 2025-07-24T17:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-study-links-glipizide-to-13-higher-cardiovascular-risk-in-type-2-diabetes-patients 2025-07-24T17:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-study-links-glipizide-to-13-higher-cardiovascular-risk-in-type-2-diabetes-patients 2025-07-24T17:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/astra-therapeutics-secures-chf-7-75-million-to-develop-novel-anti-parasitic-drugs-for-veterinary-medicine 2025-07-24T17:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astra-therapeutics-secures-chf-7-75-million-to-develop-novel-anti-parasitic-drugs-for-veterinary-medicine 2025-07-24T17:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-partners-with-matchpoint-therapeutics-in-1-billion-anti-inflammatory-drug-development-deal 2025-07-24T17:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-partners-with-matchpoint-therapeutics-in-1-billion-anti-inflammatory-drug-development-deal 2025-07-24T17:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/biostate-ai-expands-global-precision-medicine-platform-through-strategic-partnerships-in-us-china-and-india 2025-07-24T17:29:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostate-ai-expands-global-precision-medicine-platform-through-strategic-partnerships-in-us-china-and-india 2025-07-24T17:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-shows-ibogaine-dramatically-reduces-ptsd-and-depression-in-veterans-with-traumatic-brain-injury 2025-07-24T17:27:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-shows-ibogaine-dramatically-reduces-ptsd-and-depression-in-veterans-with-traumatic-brain-injury 2025-07-24T17:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-for-flibanserin-expansion-to-postmenopausal-women-with-hsdd 2025-07-24T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-for-flibanserin-expansion-to-postmenopausal-women-with-hsdd 2025-07-24T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-scientists-develop-shelf-stable-synthetic-blood-for-emergency-medicine 2025-07-24T17:26:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maryland-scientists-develop-shelf-stable-synthetic-blood-for-emergency-medicine 2025-07-24T17:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-insulin-successfully-reaches-memory-centers-in-alzheimer-s-brain-imaging-study 2025-07-24T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-insulin-successfully-reaches-memory-centers-in-alzheimer-s-brain-imaging-study 2025-07-24T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/topical-immunotherapy-shows-promise-for-severe-alopecia-areata-despite-variable-response-rates 2025-07-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topical-immunotherapy-shows-promise-for-severe-alopecia-areata-despite-variable-response-rates 2025-07-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-reports-strong-q2-2025-results-with-jakafi-growth-and-new-drug-approvals 2025-07-24T15:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-reports-strong-q2-2025-results-with-jakafi-growth-and-new-drug-approvals 2025-07-24T15:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivermectin-mass-treatment-reduces-malaria-transmission-by-26-in-landmark-bohemia-trial 2025-07-24T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivermectin-mass-treatment-reduces-malaria-transmission-by-26-in-landmark-bohemia-trial 2025-07-24T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-advances-dual-pipeline-strategy-with-novel-therapeutics-for-neurological-and-metabolic-disorders 2025-07-24T13:27:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-advances-dual-pipeline-strategy-with-novel-therapeutics-for-neurological-and-metabolic-disorders 2025-07-24T13:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/turbine-partners-with-astrazeneca-to-accelerate-adc-discovery-using-ai-powered-virtual-disease-models 2025-07-24T13:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turbine-partners-with-astrazeneca-to-accelerate-adc-discovery-using-ai-powered-virtual-disease-models 2025-07-24T13:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/kling-bio-partners-with-sanofi-to-develop-next-generation-antiviral-antibodies-using-proprietary-b-cell-platform 2025-07-24T13:26:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kling-bio-partners-with-sanofi-to-develop-next-generation-antiviral-antibodies-using-proprietary-b-cell-platform 2025-07-24T13:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-ai-model-pdgrapher-accelerates-drug-discovery-by-predicting-cellular-disease-reversal 2025-07-24T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-ai-model-pdgrapher-accelerates-drug-discovery-by-predicting-cellular-disease-reversal 2025-07-24T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-nears-completion-of-phase-2-3-als-trial-as-combat-als-study-approaches-full-enrollment 2025-07-24T13:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-nears-completion-of-phase-2-3-als-trial-as-combat-als-study-approaches-full-enrollment 2025-07-24T13:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/annexin-pharmaceuticals-receives-uk-approval-for-phase-2a-study-of-anxv-in-diabetic-retinopathy 2025-07-24T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexin-pharmaceuticals-receives-uk-approval-for-phase-2a-study-of-anxv-in-diabetic-retinopathy 2025-07-24T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/tulsi-therapeutics-achieves-100-liver-regeneration-in-world-s-first-stem-cell-exosome-therapy-trial 2025-07-24T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tulsi-therapeutics-achieves-100-liver-regeneration-in-world-s-first-stem-cell-exosome-therapy-trial 2025-07-24T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsy-drug-pipeline-shows-robust-growth-with-90-therapies-in-development-across-75-companies 2025-07-24T09:23:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epilepsy-drug-pipeline-shows-robust-growth-with-90-therapies-in-development-across-75-companies 2025-07-24T09:23:39+00:00 hourly 0.9 https://trial.medpath.com/news/dna-plasmid-therapy-elenagen-shows-90-success-rate-in-treating-chronic-pain-in-dogs-signals-non-opioid-path-for-human-medicine 2025-07-24T09:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dna-plasmid-therapy-elenagen-shows-90-success-rate-in-treating-chronic-pain-in-dogs-signals-non-opioid-path-for-human-medicine 2025-07-24T09:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/llama-derived-nanobody-shows-promise-for-schizophrenia-cognitive-symptoms-in-preclinical-study 2025-07-24T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/llama-derived-nanobody-shows-promise-for-schizophrenia-cognitive-symptoms-in-preclinical-study 2025-07-24T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/bridging-radiotherapy-shows-promise-in-reducing-car-t-cell-therapy-toxicity-across-b-cell-lymphoma-and-multiple-myeloma 2025-07-24T05:25:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridging-radiotherapy-shows-promise-in-reducing-car-t-cell-therapy-toxicity-across-b-cell-lymphoma-and-multiple-myeloma 2025-07-24T05:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/aicuris-pritelivir-achieves-superior-efficacy-in-phase-3-trial-for-refractory-hsv-in-immunocompromised-patients 2025-07-24T05:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aicuris-pritelivir-achieves-superior-efficacy-in-phase-3-trial-for-refractory-hsv-in-immunocompromised-patients 2025-07-24T05:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/quanta-therapeutics-advances-kras-g12d-inhibitor-qtx3034-to-dose-expansion-phase-following-positive-safety-data 2025-07-24T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanta-therapeutics-advances-kras-g12d-inhibitor-qtx3034-to-dose-expansion-phase-following-positive-safety-data 2025-07-24T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-astellas-successfully-defend-prostate-cancer-drug-patent-against-generic-challenge 2025-07-24T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-and-astellas-successfully-defend-prostate-cancer-drug-patent-against-generic-challenge 2025-07-24T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/hillhurst-biopharmaceuticals-initiates-phase-2a-trial-of-oral-carbon-monoxide-therapy-for-sickle-cell-disease 2025-07-24T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillhurst-biopharmaceuticals-initiates-phase-2a-trial-of-oral-carbon-monoxide-therapy-for-sickle-cell-disease 2025-07-24T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/australia-s-national-reconstruction-fund-invests-150m-in-brandon-capital-to-retain-biotech-innovation-onshore 2025-07-24T01:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-s-national-reconstruction-fund-invests-150m-in-brandon-capital-to-retain-biotech-innovation-onshore 2025-07-24T01:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-raises-747-5-million-in-public-offering-to-advance-ulcerative-colitis-drug-development 2025-07-24T01:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-raises-747-5-million-in-public-offering-to-advance-ulcerative-colitis-drug-development 2025-07-24T01:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-becomes-first-country-to-enable-point-of-care-manufacturing-for-personalized-therapies 2025-07-23T21:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-becomes-first-country-to-enable-point-of-care-manufacturing-for-personalized-therapies 2025-07-23T21:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/qu-biologics-completes-enrollment-in-phase-2-trial-testing-novel-immunomodulator-for-age-related-immune-decline 2025-07-23T21:29:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qu-biologics-completes-enrollment-in-phase-2-trial-testing-novel-immunomodulator-for-age-related-immune-decline 2025-07-23T21:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-wins-patent-battle-against-novo-nordisk-over-generic-wegovy 2025-07-23T21:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-wins-patent-battle-against-novo-nordisk-over-generic-wegovy 2025-07-23T21:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-dismisses-whistleblower-patent-fraud-lawsuit-against-valeant-and-salix-over-ulcerative-colitis-drug-apriso 2025-07-23T21:27:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-dismisses-whistleblower-patent-fraud-lawsuit-against-valeant-and-salix-over-ulcerative-colitis-drug-apriso 2025-07-23T21:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/autoantibodies-emerge-as-key-predictors-of-cancer-immunotherapy-response-boosting-effectiveness-up-to-10-fold 2025-07-23T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autoantibodies-emerge-as-key-predictors-of-cancer-immunotherapy-response-boosting-effectiveness-up-to-10-fold 2025-07-23T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-advanced-uronav-system-for-precision-focal-therapy-in-prostate-cancer 2025-07-23T21:27:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-advanced-uronav-system-for-precision-focal-therapy-in-prostate-cancer 2025-07-23T21:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-shows-promise-for-fertility-restoration-in-women-with-ovarian-failure 2025-07-23T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-therapy-shows-promise-for-fertility-restoration-in-women-with-ovarian-failure 2025-07-23T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-researchers-develop-gene-therapy-to-reactivate-silent-genes-in-rett-syndrome 2025-07-23T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-researchers-develop-gene-therapy-to-reactivate-silent-genes-in-rett-syndrome 2025-07-23T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/legacy-healthcare-s-cinainu-shows-sustained-hair-regrowth-in-pediatric-alopecia-areata-phase-2-3-trial 2025-07-23T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legacy-healthcare-s-cinainu-shows-sustained-hair-regrowth-in-pediatric-alopecia-areata-phase-2-3-trial 2025-07-23T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/atopic-dermatitis-market-poised-for-four-fold-growth-by-2034-driven-by-novel-il-13-inhibitor-approvals 2025-07-23T21:25:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atopic-dermatitis-market-poised-for-four-fold-growth-by-2034-driven-by-novel-il-13-inhibitor-approvals 2025-07-23T21:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-triples-global-oncology-research-network-expanding-real-world-data-access-across-three-countries 2025-07-23T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-triples-global-oncology-research-network-expanding-real-world-data-access-across-three-countries 2025-07-23T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-chemists-overcome-solubility-issues-in-next-generation-malaria-drug-through-molecular-redesign 2025-07-23T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-chemists-overcome-solubility-issues-in-next-generation-malaria-drug-through-molecular-redesign 2025-07-23T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/ai-guided-drug-lp-284-achieves-complete-response-in-treatment-resistant-lymphoma-patient 2025-07-23T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-guided-drug-lp-284-achieves-complete-response-in-treatment-resistant-lymphoma-patient 2025-07-23T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-anti-tslp-antibody-hbm9378-win378-enters-global-phase-2-trial-for-asthma-treatment 2025-07-23T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-anti-tslp-antibody-hbm9378-win378-enters-global-phase-2-trial-for-asthma-treatment 2025-07-23T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/neuroone-receives-uspto-patent-approval-for-novel-neural-probe-manufacturing-technology 2025-07-23T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroone-receives-uspto-patent-approval-for-novel-neural-probe-manufacturing-technology 2025-07-23T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-secures-key-patent-for-albumin-free-hyaluronidase-formulation-advances-toward-2026-market-authorization 2025-07-23T17:29:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huonslab-secures-key-patent-for-albumin-free-hyaluronidase-formulation-advances-toward-2026-market-authorization 2025-07-23T17:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-restructures-executive-leadership-with-three-key-appointments-to-drive-growth-in-oncology-and-rare-disease 2025-07-23T17:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-restructures-executive-leadership-with-three-key-appointments-to-drive-growth-in-oncology-and-rare-disease 2025-07-23T17:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/former-poseida-ceo-kristin-yarema-named-to-lead-ikena-inmagene-merger-as-companies-advance-anti-ox40-therapy 2025-07-23T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-poseida-ceo-kristin-yarema-named-to-lead-ikena-inmagene-merger-as-companies-advance-anti-ox40-therapy 2025-07-23T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-partners-with-dndi-to-advance-oral-chagas-disease-treatment-an2-502998 2025-07-23T17:28:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an2-therapeutics-partners-with-dndi-to-advance-oral-chagas-disease-treatment-an2-502998 2025-07-23T17:28:32+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-data-support-mvasi-biosimilar-as-viable-alternative-for-retinal-disease-treatment 2025-07-23T17:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-data-support-mvasi-biosimilar-as-viable-alternative-for-retinal-disease-treatment 2025-07-23T17:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/epicore-biosystems-secures-1-2m-military-contract-for-smart-hydration-wearables 2025-07-23T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epicore-biosystems-secures-1-2m-military-contract-for-smart-hydration-wearables 2025-07-23T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-unveils-ai-powered-alzheimer-s-platforms-at-aaic-2025 2025-07-23T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-unveils-ai-powered-alzheimer-s-platforms-at-aaic-2025 2025-07-23T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-advances-pd-1-vegf-bispecific-antibody-ai-081-to-phase-2-trial-following-promising-early-efficacy-data 2025-07-23T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoc4-advances-pd-1-vegf-bispecific-antibody-ai-081-to-phase-2-trial-following-promising-early-efficacy-data 2025-07-23T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/radiation-therapy-overcomes-primary-resistance-to-pembrolizumab-in-immunologically-cold-nsclc 2025-07-23T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiation-therapy-overcomes-primary-resistance-to-pembrolizumab-in-immunologically-cold-nsclc 2025-07-23T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/inotrem-s-precision-medicine-strategy-shows-breakthrough-results-for-septic-shock-treatment-with-nangibotide 2025-07-23T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inotrem-s-precision-medicine-strategy-shows-breakthrough-results-for-septic-shock-treatment-with-nangibotide 2025-07-23T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-avidity-s-del-zota-for-duchenne-muscular-dystrophy 2025-07-23T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-avidity-s-del-zota-for-duchenne-muscular-dystrophy 2025-07-23T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-launches-two-major-initiatives-to-accelerate-vaccine-development-and-regulatory-approval-in-disease-outbreaks 2025-07-23T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-launches-two-major-initiatives-to-accelerate-vaccine-development-and-regulatory-approval-in-disease-outbreaks 2025-07-23T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-landscape-for-alopecia-universalis-reveals-growing-research-activity-across-major-pharmaceutical-companies 2025-07-23T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trials-landscape-for-alopecia-universalis-reveals-growing-research-activity-across-major-pharmaceutical-companies 2025-07-23T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/cycle-pharmaceuticals-secures-exclusive-u-s-rights-to-phyrago-novel-dasatinib-formulation-for-leukemia-treatment 2025-07-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cycle-pharmaceuticals-secures-exclusive-u-s-rights-to-phyrago-novel-dasatinib-formulation-for-leukemia-treatment 2025-07-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-hospitals-and-siemens-healthineers-launch-ai-driven-research-collaboration-for-liver-disease-diagnostics-in-india 2025-07-23T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apollo-hospitals-and-siemens-healthineers-launch-ai-driven-research-collaboration-for-liver-disease-diagnostics-in-india 2025-07-23T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-launches-beova-tablets-for-overactive-bladder-treatment-in-thailand 2025-07-23T13:29:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-launches-beova-tablets-for-overactive-bladder-treatment-in-thailand 2025-07-23T13:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/crown-bioscience-san-diego-receives-clia-certification-to-expand-clinical-testing-capabilities 2025-07-23T13:27:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crown-bioscience-san-diego-receives-clia-certification-to-expand-clinical-testing-capabilities 2025-07-23T13:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/iluvien-shows-mixed-results-in-new-day-trial-for-diabetic-macular-edema-treatment 2025-07-23T13:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iluvien-shows-mixed-results-in-new-day-trial-for-diabetic-macular-edema-treatment 2025-07-23T13:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/c-mic-ii-trial-shows-microcurrent-therapy-significantly-improves-heart-function-in-heart-failure-patients 2025-07-23T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-mic-ii-trial-shows-microcurrent-therapy-significantly-improves-heart-function-in-heart-failure-patients 2025-07-23T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/bd-libertas-wearable-injector-enters-first-pharma-sponsored-clinical-trial-for-complex-biologics-delivery 2025-07-23T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-libertas-wearable-injector-enters-first-pharma-sponsored-clinical-trial-for-complex-biologics-delivery 2025-07-23T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/bio-usawa-and-servaregmp-partner-to-establish-monoclonal-antibody-manufacturing-in-africa 2025-07-23T13:23:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-usawa-and-servaregmp-partner-to-establish-monoclonal-antibody-manufacturing-in-africa 2025-07-23T13:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/dispatch-bio-emerges-with-216m-to-develop-universal-solid-tumor-immunotherapy 2025-07-23T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dispatch-bio-emerges-with-216m-to-develop-universal-solid-tumor-immunotherapy 2025-07-23T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/dapagliflozin-demonstrates-sustained-cardiovascular-benefits-in-long-term-diabetes-study 2025-07-23T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dapagliflozin-demonstrates-sustained-cardiovascular-benefits-in-long-term-diabetes-study 2025-07-23T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/ghana-fda-and-company-deny-coa-72-hiv-clinical-trial-claims-following-media-misinformation 2025-07-23T09:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ghana-fda-and-company-deny-coa-72-hiv-clinical-trial-claims-following-media-misinformation 2025-07-23T09:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/a-forall-launches-direct-commercialization-of-sodium-acetate-injection-to-address-u-s-drug-shortage 2025-07-23T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-forall-launches-direct-commercialization-of-sodium-acetate-injection-to-address-u-s-drug-shortage 2025-07-23T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/csl-behring-s-australian-plasma-facility-wins-global-manufacturing-excellence-award-for-advanced-automation 2025-07-23T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-behring-s-australian-plasma-facility-wins-global-manufacturing-excellence-award-for-advanced-automation 2025-07-23T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-expands-nepexto-biosimilar-to-australian-market-for-autoimmune-disease-treatment 2025-07-23T09:22:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-expands-nepexto-biosimilar-to-australian-market-for-autoimmune-disease-treatment 2025-07-23T09:22:30+00:00 hourly 0.9 https://trial.medpath.com/news/ulonivirine-shows-promise-for-once-weekly-hiv-treatment-despite-early-trial-setback 2025-07-23T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ulonivirine-shows-promise-for-once-weekly-hiv-treatment-despite-early-trial-setback 2025-07-23T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/syntellix-secures-nmpa-approval-for-bioabsorbable-metallic-implants-in-china-unlocking-1-4-billion-patient-market 2025-07-23T09:21:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syntellix-secures-nmpa-approval-for-bioabsorbable-metallic-implants-in-china-unlocking-1-4-billion-patient-market 2025-07-23T09:21:53+00:00 hourly 0.9 https://trial.medpath.com/news/pfas-forever-chemicals-linked-to-31-increased-risk-of-type-2-diabetes 2025-07-23T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfas-forever-chemicals-linked-to-31-increased-risk-of-type-2-diabetes 2025-07-23T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/hesperos-achieves-first-digital-twin-of-human-disease-using-malaria-on-a-chip-platform 2025-07-23T05:21:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hesperos-achieves-first-digital-twin-of-human-disease-using-malaria-on-a-chip-platform 2025-07-23T05:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/american-gene-technologies-reports-sustained-hiv-reservoir-reduction-in-phase-1-trial-of-agt103-t-cell-therapy 2025-07-23T05:21:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-gene-technologies-reports-sustained-hiv-reservoir-reduction-in-phase-1-trial-of-agt103-t-cell-therapy 2025-07-23T05:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/kidney-cancer-research-consortium-advances-novel-combination-therapies-through-multi-institutional-collaboration 2025-07-23T02:57:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kidney-cancer-research-consortium-advances-novel-combination-therapies-through-multi-institutional-collaboration 2025-07-23T02:57:14+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-pharma-raises-100m-to-advance-inhaled-pulmonary-fibrosis-therapies 2025-07-23T01:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalyn-pharma-raises-100m-to-advance-inhaled-pulmonary-fibrosis-therapies 2025-07-23T01:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/novel-csf-biomarkers-chit1-and-ddah1-may-predict-aria-risk-in-alzheimer-s-patients-receiving-anti-amyloid-therapies 2025-07-23T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-csf-biomarkers-chit1-and-ddah1-may-predict-aria-risk-in-alzheimer-s-patients-receiving-anti-amyloid-therapies 2025-07-23T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-raises-1-74-million-to-advance-immunology-and-oncology-pipeline 2025-07-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tharimmune-raises-1-74-million-to-advance-immunology-and-oncology-pipeline 2025-07-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-3d-printed-epilepsy-drug-for-feeding-tube-administration 2025-07-22T21:29:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-3d-printed-epilepsy-drug-for-feeding-tube-administration 2025-07-22T21:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-partners-with-johnson-johnson-to-expand-zilretta-access-for-osteoarthritis-knee-pain 2025-07-22T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-biosciences-partners-with-johnson-johnson-to-expand-zilretta-access-for-osteoarthritis-knee-pain 2025-07-22T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-acquires-iteos-therapeutics-for-10-05-per-share-following-tigit-program-failure 2025-07-22T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concentra-biosciences-acquires-iteos-therapeutics-for-10-05-per-share-following-tigit-program-failure 2025-07-22T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-radiation-free-stem-cell-transplant-protocol-for-fanconi-anemia-patients 2025-07-22T21:24:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-develop-radiation-free-stem-cell-transplant-protocol-for-fanconi-anemia-patients 2025-07-22T21:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/stride-immunotherapy-achieves-unprecedented-19-6-five-year-survival-rate-in-advanced-liver-cancer 2025-07-22T21:23:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stride-immunotherapy-achieves-unprecedented-19-6-five-year-survival-rate-in-advanced-liver-cancer 2025-07-22T21:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-daratumumab-formulation-reduces-treatment-time-and-premedication-requirements-in-multiple-myeloma 2025-07-22T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-daratumumab-formulation-reduces-treatment-time-and-premedication-requirements-in-multiple-myeloma 2025-07-22T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/hmnc-brain-health-and-spruce-biosciences-launch-phase-2-trial-for-precision-depression-treatment 2025-07-22T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmnc-brain-health-and-spruce-biosciences-launch-phase-2-trial-for-precision-depression-treatment 2025-07-22T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/precision-genomic-profiling-reveals-multiple-molecular-diagnoses-in-gaucher-disease-patients-with-atypical-presentations 2025-07-22T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-genomic-profiling-reveals-multiple-molecular-diagnoses-in-gaucher-disease-patients-with-atypical-presentations 2025-07-22T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-adalimumab-biosimilar-ibi303-matches-humira-efficacy-with-superior-cost-benefits-in-ankylosing-spondylitis 2025-07-22T21:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-adalimumab-biosimilar-ibi303-matches-humira-efficacy-with-superior-cost-benefits-in-ankylosing-spondylitis 2025-07-22T21:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-replimune-s-melanoma-drug-amid-evolving-regulatory-standards 2025-07-22T21:21:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-replimune-s-melanoma-drug-amid-evolving-regulatory-standards 2025-07-22T21:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/nanoknife-system-shows-promise-for-prostate-cancer-treatment-in-preserve-trial 2025-07-22T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoknife-system-shows-promise-for-prostate-cancer-treatment-in-preserve-trial 2025-07-22T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/sintx-technologies-submits-fda-510-k-for-silicon-nitride-foot-and-ankle-implants 2025-07-22T21:20:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sintx-technologies-submits-fda-510-k-for-silicon-nitride-foot-and-ankle-implants 2025-07-22T21:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-achieves-100-fda-inspection-success-rate-with-five-facilities-passing-pre-license-review 2025-07-22T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-achieves-100-fda-inspection-success-rate-with-five-facilities-passing-pre-license-review 2025-07-22T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-theranostics-appoints-leading-prostate-cancer-expert-dr-oliver-sartor-to-scientific-advisory-board 2025-07-22T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharm-theranostics-appoints-leading-prostate-cancer-expert-dr-oliver-sartor-to-scientific-advisory-board 2025-07-22T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-phase-iii-trials-for-two-novel-cardiovascular-fixed-dose-combinations 2025-07-22T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-phase-iii-trials-for-two-novel-cardiovascular-fixed-dose-combinations 2025-07-22T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-strengthens-board-with-neuroscience-and-finance-veterans-as-bezisterim-advances-through-phase-2-trials 2025-07-22T17:30:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovie-strengthens-board-with-neuroscience-and-finance-veterans-as-bezisterim-advances-through-phase-2-trials 2025-07-22T17:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/cgt-catapult-invests-in-spliceor-s-trans-splicing-gene-therapy-platform-for-liver-cancer 2025-07-22T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cgt-catapult-invests-in-spliceor-s-trans-splicing-gene-therapy-platform-for-liver-cancer 2025-07-22T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-receives-gene-therapy-for-ultra-rare-nedamss-disease-in-record-13-month-timeline 2025-07-22T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-receives-gene-therapy-for-ultra-rare-nedamss-disease-in-record-13-month-timeline 2025-07-22T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/ixico-secures-full-data-rights-to-landmark-bio-hermes-002-alzheimer-s-study-through-strategic-gap-partnership 2025-07-22T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ixico-secures-full-data-rights-to-landmark-bio-hermes-002-alzheimer-s-study-through-strategic-gap-partnership 2025-07-22T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-discontinues-rare-pediatric-disease-designation-program-despite-rising-approval-trends 2025-07-22T17:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-discontinues-rare-pediatric-disease-designation-program-despite-rising-approval-trends 2025-07-22T17:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/alto-neuroscience-faces-class-action-lawsuit-following-alto-100-phase-2b-trial-failure 2025-07-22T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alto-neuroscience-faces-class-action-lawsuit-following-alto-100-phase-2b-trial-failure 2025-07-22T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/medunik-usa-expands-siklos-r-medicaid-coverage-to-37-states-improving-access-for-sickle-cell-disease-patients 2025-07-22T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medunik-usa-expands-siklos-r-medicaid-coverage-to-37-states-improving-access-for-sickle-cell-disease-patients 2025-07-22T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/coriolis-pharma-invests-10-million-in-north-carolina-laboratory-to-expand-biopharmaceutical-development-services 2025-07-22T17:25:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coriolis-pharma-invests-10-million-in-north-carolina-laboratory-to-expand-biopharmaceutical-development-services 2025-07-22T17:25:57+00:00 hourly 0.9 https://trial.medpath.com/news/q3-2025-biopharma-catalyst-monitor-highlights-18-key-fda-decisions-and-clinical-trial-milestones 2025-07-22T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/q3-2025-biopharma-catalyst-monitor-highlights-18-key-fda-decisions-and-clinical-trial-milestones 2025-07-22T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/surgivance-secures-2-2m-nih-grant-to-advance-direct-to-digital-pathology-platform 2025-07-22T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgivance-secures-2-2m-nih-grant-to-advance-direct-to-digital-pathology-platform 2025-07-22T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/seres-therapeutics-appoints-co-ceos-as-company-seeks-partnerships-for-ser-155-development 2025-07-22T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seres-therapeutics-appoints-co-ceos-as-company-seeks-partnerships-for-ser-155-development 2025-07-22T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/estonian-biotech-aio-secures-eur1m-grant-to-develop-sustainable-cosmetics-ingredients-through-yeast-fermentation 2025-07-22T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/estonian-biotech-aio-secures-eur1m-grant-to-develop-sustainable-cosmetics-ingredients-through-yeast-fermentation 2025-07-22T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/answer-als-launches-ai-powered-drug-discovery-initiative-to-accelerate-als-treatment-development 2025-07-22T17:24:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/answer-als-launches-ai-powered-drug-discovery-initiative-to-accelerate-als-treatment-development 2025-07-22T17:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-partners-with-fda-to-establish-regulatory-standards-for-antibody-drug-conjugates 2025-07-22T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sutro-biopharma-partners-with-fda-to-establish-regulatory-standards-for-antibody-drug-conjugates 2025-07-22T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/osteochondral-organoids-emerge-as-breakthrough-platform-for-osteoarthritis-research-and-therapy 2025-07-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osteochondral-organoids-emerge-as-breakthrough-platform-for-osteoarthritis-research-and-therapy 2025-07-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cooler-heads-raises-11m-series-a-to-expand-fda-cleared-scalp-cooling-system-for-chemotherapy-patients 2025-07-22T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cooler-heads-raises-11m-series-a-to-expand-fda-cleared-scalp-cooling-system-for-chemotherapy-patients 2025-07-22T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-of-canada-to-rule-on-medical-treatment-patent-eligibility-in-landmark-pharmascience-v-janssen-case 2025-07-22T13:23:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-of-canada-to-rule-on-medical-treatment-patent-eligibility-in-landmark-pharmascience-v-janssen-case 2025-07-22T13:23:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requests-additional-manufacturing-data-for-telix-s-kidney-cancer-diagnostic-drug-zircaix 2025-07-22T13:23:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-requests-additional-manufacturing-data-for-telix-s-kidney-cancer-diagnostic-drug-zircaix 2025-07-22T13:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-shares-surge-14-on-amtagvi-fda-approval-and-new-ceo-appointment 2025-07-22T13:22:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-shares-surge-14-on-amtagvi-fda-approval-and-new-ceo-appointment 2025-07-22T13:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/phoremost-unveils-glueseeker-platform-to-accelerate-rational-molecular-glue-drug-discovery 2025-07-22T13:22:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phoremost-unveils-glueseeker-platform-to-accelerate-rational-molecular-glue-drug-discovery 2025-07-22T13:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/eyam-health-and-mmv-partner-to-develop-1-malaria-prevention-shot-using-ai-designed-monoclonal-antibodies 2025-07-22T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyam-health-and-mmv-partner-to-develop-1-malaria-prevention-shot-using-ai-designed-monoclonal-antibodies 2025-07-22T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-replimune-s-rp1-melanoma-therapy-citing-trial-design-concerns 2025-07-22T13:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-replimune-s-rp1-melanoma-therapy-citing-trial-design-concerns 2025-07-22T13:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-acquires-vicebio-for-1-15-billion-to-expand-respiratory-vaccine-pipeline-with-molecular-clamp-technology 2025-07-22T13:20:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-acquires-vicebio-for-1-15-billion-to-expand-respiratory-vaccine-pipeline-with-molecular-clamp-technology 2025-07-22T13:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/failed-long-covid-drug-trial-reveals-critical-study-design-flaws-as-new-company-plans-restart 2025-07-22T13:19:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/failed-long-covid-drug-trial-reveals-critical-study-design-flaws-as-new-company-plans-restart 2025-07-22T13:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/new-clinical-trials-market-reports-highlight-global-research-landscape-for-vitamin-b12-deficiency-and-hypoglycemia 2025-07-22T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-clinical-trials-market-reports-highlight-global-research-landscape-for-vitamin-b12-deficiency-and-hypoglycemia 2025-07-22T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-completes-789-million-acquisition-of-life-molecular-imaging-gains-fda-approved-alzheimer-s-diagnostic-agent 2025-07-22T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-completes-789-million-acquisition-of-life-molecular-imaging-gains-fda-approved-alzheimer-s-diagnostic-agent 2025-07-22T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-receives-fda-approval-for-genio-neuromodulation-device-to-treat-sleep-apnea 2025-07-22T09:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-receives-fda-approval-for-genio-neuromodulation-device-to-treat-sleep-apnea 2025-07-22T09:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharmaceutical-enters-biosimilar-market-with-former-celltrion-executive-leading-new-division 2025-07-22T09:23:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daewoong-pharmaceutical-enters-biosimilar-market-with-former-celltrion-executive-leading-new-division 2025-07-22T09:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/zepbound-receives-health-canada-approval-as-first-dual-receptor-obesity-treatment 2025-07-22T09:22:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zepbound-receives-health-canada-approval-as-first-dual-receptor-obesity-treatment 2025-07-22T09:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-advances-loxo-435-in-phase-1-forager-1-study-for-fgfr3-altered-advanced-cancers 2025-07-22T05:21:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-advances-loxo-435-in-phase-1-forager-1-study-for-fgfr3-altered-advanced-cancers 2025-07-22T05:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-patient-priorities-in-advanced-colorectal-cancer-treatment-decision-making 2025-07-22T05:21:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-reveals-patient-priorities-in-advanced-colorectal-cancer-treatment-decision-making 2025-07-22T05:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-expands-workforce-with-stock-option-grants-for-new-employees 2025-07-22T02:55:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-expands-workforce-with-stock-option-grants-for-new-employees 2025-07-22T02:55:37+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-licenses-novel-cardiac-stem-cell-technology-to-address-safety-concerns-in-heart-disease-treatment 2025-07-22T01:28:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longeveron-licenses-novel-cardiac-stem-cell-technology-to-address-safety-concerns-in-heart-disease-treatment 2025-07-22T01:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-drugs-show-promise-as-first-prophylactic-treatment-for-htlv-1-virus-in-landmark-australian-study 2025-07-22T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-drugs-show-promise-as-first-prophylactic-treatment-for-htlv-1-virus-in-landmark-australian-study 2025-07-22T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/dualitybio-s-her3-targeting-adc-db-1310-receives-fda-fast-track-designation-for-egfr-mutant-lung-cancer 2025-07-22T01:24:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dualitybio-s-her3-targeting-adc-db-1310-receives-fda-fast-track-designation-for-egfr-mutant-lung-cancer 2025-07-22T01:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-announces-50-billion-us-investment-plan-with-virginia-manufacturing-hub-for-weight-management-and-metabolic-drugs 2025-07-22T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-announces-50-billion-us-investment-plan-with-virginia-manufacturing-hub-for-weight-management-and-metabolic-drugs 2025-07-22T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/casi-pharmaceuticals-names-david-cory-ceo-to-advance-anti-cd38-antibody-cid-103-program 2025-07-22T01:22:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/casi-pharmaceuticals-names-david-cory-ceo-to-advance-anti-cd38-antibody-cid-103-program 2025-07-22T01:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-takeda-s-hyhub-devices-to-streamline-at-home-hyqvia-immunoglobulin-therapy 2025-07-22T01:22:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-takeda-s-hyhub-devices-to-streamline-at-home-hyqvia-immunoglobulin-therapy 2025-07-22T01:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/extended-paxlovid-treatment-reduces-viral-rebound-in-immunocompromised-covid-19-patients 2025-07-21T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-paxlovid-treatment-reduces-viral-rebound-in-immunocompromised-covid-19-patients 2025-07-21T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/livzon-s-dual-target-il-17a-f-antibody-lzm012-outperforms-secukinumab-in-phase-iii-psoriasis-trial 2025-07-21T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livzon-s-dual-target-il-17a-f-antibody-lzm012-outperforms-secukinumab-in-phase-iii-psoriasis-trial 2025-07-21T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccine-effectiveness-studies-show-waning-protection-over-time-supporting-annual-vaccination 2025-07-21T21:26:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-vaccine-effectiveness-studies-show-waning-protection-over-time-supporting-annual-vaccination 2025-07-21T21:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expert-panel-debates-ssri-safety-during-pregnancy-amid-calls-for-stronger-warnings 2025-07-21T21:26:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expert-panel-debates-ssri-safety-during-pregnancy-amid-calls-for-stronger-warnings 2025-07-21T21:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/ausperbio-receives-china-cde-clearance-for-phase-iii-trial-of-hepatitis-b-antisense-therapy-ahb-137 2025-07-21T21:26:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ausperbio-receives-china-cde-clearance-for-phase-iii-trial-of-hepatitis-b-antisense-therapy-ahb-137 2025-07-21T21:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/nestmedic-partners-with-curavit-for-u-s-clinical-trial-of-ai-enabled-prenatal-monitoring-device 2025-07-21T21:25:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nestmedic-partners-with-curavit-for-u-s-clinical-trial-of-ai-enabled-prenatal-monitoring-device 2025-07-21T21:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-study-challenges-decades-of-cholesterol-concerns-about-eggs 2025-07-21T17:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-study-challenges-decades-of-cholesterol-concerns-about-eggs 2025-07-21T17:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-trial-introduces-adaptive-parp-inhibitor-strategy-for-metastatic-prostate-cancer-with-focus-on-underrepresented-populations 2025-07-21T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-trial-introduces-adaptive-parp-inhibitor-strategy-for-metastatic-prostate-cancer-with-focus-on-underrepresented-populations 2025-07-21T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/nanogel-armed-car-t-cells-achieve-83-2-tumor-inhibition-rate-in-solid-tumor-model 2025-07-21T17:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanogel-armed-car-t-cells-achieve-83-2-tumor-inhibition-rate-in-solid-tumor-model 2025-07-21T17:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-therapeutics-advances-novel-car-gamma-delta-t-cell-therapy-to-phase-i-dose-level-2 2025-07-21T17:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomed-therapeutics-advances-novel-car-gamma-delta-t-cell-therapy-to-phase-i-dose-level-2 2025-07-21T17:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/promis-neurosciences-receives-fda-fast-track-designation-for-alzheimer-s-drug-pmn310 2025-07-21T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promis-neurosciences-receives-fda-fast-track-designation-for-alzheimer-s-drug-pmn310 2025-07-21T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/epirium-bio-completes-first-in-human-trial-of-novel-oral-sarcopenia-treatment-mf-300 2025-07-21T17:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epirium-bio-completes-first-in-human-trial-of-novel-oral-sarcopenia-treatment-mf-300 2025-07-21T17:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/medgenome-secures-47-5-million-series-e-funding-to-expand-genomic-diagnostics-access-across-india 2025-07-21T17:29:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medgenome-secures-47-5-million-series-e-funding-to-expand-genomic-diagnostics-access-across-india 2025-07-21T17:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-therapeutics-secures-30-1-million-to-advance-dm199-for-preeclampsia-and-fetal-growth-restriction 2025-07-21T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamedica-therapeutics-secures-30-1-million-to-advance-dm199-for-preeclampsia-and-fetal-growth-restriction 2025-07-21T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-secures-european-patent-for-ai-developed-cancer-therapy-lp-284 2025-07-21T17:27:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-secures-european-patent-for-ai-developed-cancer-therapy-lp-284 2025-07-21T17:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-orforglipron-shows-promise-as-oral-glp-1-therapy-advances 2025-07-21T17:26:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-orforglipron-shows-promise-as-oral-glp-1-therapy-advances 2025-07-21T17:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/mvp-health-care-partners-with-renalytix-to-expand-access-to-ai-powered-kidney-disease-testing 2025-07-21T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mvp-health-care-partners-with-renalytix-to-expand-access-to-ai-powered-kidney-disease-testing 2025-07-21T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/korro-bio-receives-ema-orphan-drug-designation-for-rna-editing-therapy-krro-110-in-alpha-1-antitrypsin-deficiency 2025-07-21T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korro-bio-receives-ema-orphan-drug-designation-for-rna-editing-therapy-krro-110-in-alpha-1-antitrypsin-deficiency 2025-07-21T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-receives-fda-approval-for-groundbreaking-map-targeted-crohn-s-disease-study 2025-07-21T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-receives-fda-approval-for-groundbreaking-map-targeted-crohn-s-disease-study 2025-07-21T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/cerus-corporation-secures-7-2m-dod-contract-amendment-to-advance-trauma-hemorrhage-treatment 2025-07-21T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerus-corporation-secures-7-2m-dod-contract-amendment-to-advance-trauma-hemorrhage-treatment 2025-07-21T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-appoints-biotech-veteran-george-tidmarsh-to-lead-drug-regulation-center-amid-agency-restructuring 2025-07-21T13:33:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-appoints-biotech-veteran-george-tidmarsh-to-lead-drug-regulation-center-amid-agency-restructuring 2025-07-21T13:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/gecko-inspired-nanoparticles-show-promise-for-targeted-bladder-cancer-therapy 2025-07-21T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gecko-inspired-nanoparticles-show-promise-for-targeted-bladder-cancer-therapy 2025-07-21T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ima-group-acquires-medical-research-network-to-expand-cns-clinical-trial-capabilities 2025-07-21T13:29:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ima-group-acquires-medical-research-network-to-expand-cns-clinical-trial-capabilities 2025-07-21T13:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/corteria-pharmaceuticals-advances-first-in-class-crf2-agonists-into-phase-2-heart-failure-and-phase-1-obesity-trials 2025-07-21T13:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corteria-pharmaceuticals-advances-first-in-class-crf2-agonists-into-phase-2-heart-failure-and-phase-1-obesity-trials 2025-07-21T13:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-first-in-class-birch-pollen-immunotherapy-for-severe-hayfever-on-nhs 2025-07-21T13:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-first-in-class-birch-pollen-immunotherapy-for-severe-hayfever-on-nhs 2025-07-21T13:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/alk-s-tree-pollen-tablet-itulazax-receives-nice-recommendation-for-uk-nhs-reimbursement 2025-07-21T13:27:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alk-s-tree-pollen-tablet-itulazax-receives-nice-recommendation-for-uk-nhs-reimbursement 2025-07-21T13:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/sab-bio-secures-175-million-funding-to-advance-type-1-diabetes-immunotherapy-through-phase-2b-trial 2025-07-21T13:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sab-bio-secures-175-million-funding-to-advance-type-1-diabetes-immunotherapy-through-phase-2b-trial 2025-07-21T13:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-investment-authority-invests-200-million-in-indian-medtech-company-meril 2025-07-21T13:25:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-investment-authority-invests-200-million-in-indian-medtech-company-meril 2025-07-21T13:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/alkermes-alixorexton-shows-promise-in-phase-2-narcolepsy-trial-achieving-normal-wakefulness-levels 2025-07-21T13:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkermes-alixorexton-shows-promise-in-phase-2-narcolepsy-trial-achieving-normal-wakefulness-levels 2025-07-21T13:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/omega-funds-closes-oversubscribed-647m-fund-viii-to-accelerate-life-sciences-innovation 2025-07-21T13:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omega-funds-closes-oversubscribed-647m-fund-viii-to-accelerate-life-sciences-innovation 2025-07-21T13:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-researchers-develop-gai-17-novel-stroke-drug-with-six-hour-treatment-window 2025-07-21T13:24:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-researchers-develop-gai-17-novel-stroke-drug-with-six-hour-treatment-window 2025-07-21T13:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/donidalorsen-shows-62-reduction-in-hae-attacks-when-patients-switch-from-other-prophylactics-in-phase-3-study 2025-07-21T13:23:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/donidalorsen-shows-62-reduction-in-hae-attacks-when-patients-switch-from-other-prophylactics-in-phase-3-study 2025-07-21T13:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/oncozenge-partners-with-meribel-pharma-for-bupizenge-phase-3-manufacturing 2025-07-21T13:23:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncozenge-partners-with-meribel-pharma-for-bupizenge-phase-3-manufacturing 2025-07-21T13:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/xvivo-initiates-us-continued-access-protocol-study-for-heart-assist-transport-device-following-successful-preserve-trial 2025-07-21T13:22:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xvivo-initiates-us-continued-access-protocol-study-for-heart-assist-transport-device-following-successful-preserve-trial 2025-07-21T13:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/brisk-walking-shows-significant-health-benefits-in-large-scale-studies-of-older-adults 2025-07-21T10:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brisk-walking-shows-significant-health-benefits-in-large-scale-studies-of-older-adults 2025-07-21T10:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-regulatory-changes-drive-strategic-timing-considerations-and-medical-affairs-team-adaptations 2025-07-21T09:27:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-regulatory-changes-drive-strategic-timing-considerations-and-medical-affairs-team-adaptations 2025-07-21T09:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-releases-new-sec-guidelines-to-enhance-drug-and-medical-device-approval-process 2025-07-21T09:27:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-releases-new-sec-guidelines-to-enhance-drug-and-medical-device-approval-process 2025-07-21T09:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/fangzhou-and-novo-nordisk-partner-to-create-ai-powered-chronic-disease-management-ecosystem-in-china 2025-07-21T09:27:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fangzhou-and-novo-nordisk-partner-to-create-ai-powered-chronic-disease-management-ecosystem-in-china 2025-07-21T09:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/ai-repurposed-diabetes-drug-halicin-shows-promise-against-multidrug-resistant-superbugs 2025-07-21T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-repurposed-diabetes-drug-halicin-shows-promise-against-multidrug-resistant-superbugs 2025-07-21T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-ilumya-achieves-primary-endpoints-in-two-phase-3-psoriatic-arthritis-trials 2025-07-21T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-ilumya-achieves-primary-endpoints-in-two-phase-3-psoriatic-arthritis-trials 2025-07-21T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-acquires-gilgamesh-s-breakthrough-depression-treatment-bretisilocin-for-1-2-billion 2025-07-21T09:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-acquires-gilgamesh-s-breakthrough-depression-treatment-bretisilocin-for-1-2-billion 2025-07-21T09:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/corestemchemon-partners-with-atg-lifetech-to-advance-organoid-based-preclinical-testing 2025-07-21T09:25:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corestemchemon-partners-with-atg-lifetech-to-advance-organoid-based-preclinical-testing 2025-07-21T09:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/cloudbreak-pharma-s-cbt-004-achieves-primary-endpoint-in-phase-2-trial-for-vascularized-pinguecula 2025-07-21T09:25:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cloudbreak-pharma-s-cbt-004-achieves-primary-endpoint-in-phase-2-trial-for-vascularized-pinguecula 2025-07-21T09:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-astegolimab-shows-mixed-results-in-copd-trials-phase-iib-study-meets-primary-endpoint 2025-07-21T09:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-astegolimab-shows-mixed-results-in-copd-trials-phase-iib-study-meets-primary-endpoint 2025-07-21T09:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/venus-remedies-receives-who-gdp-certification-for-advanced-digital-logistics-operations 2025-07-21T09:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venus-remedies-receives-who-gdp-certification-for-advanced-digital-logistics-operations 2025-07-21T09:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-launches-new-glioblastoma-trial-after-patient-shows-complete-tumor-clearance-with-ipilimumab 2025-07-21T09:24:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-launches-new-glioblastoma-trial-after-patient-shows-complete-tumor-clearance-with-ipilimumab 2025-07-21T09:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-researchers-begin-human-trials-for-revolutionary-tooth-regeneration-drug 2025-07-21T09:23:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-researchers-begin-human-trials-for-revolutionary-tooth-regeneration-drug 2025-07-21T09:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/protalix-biotherapeutics-appoints-gilad-mamlok-as-new-cfo-to-drive-growth-strategy 2025-07-21T03:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protalix-biotherapeutics-appoints-gilad-mamlok-as-new-cfo-to-drive-growth-strategy 2025-07-21T03:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-gut-bacteria-shows-promise-in-phase-1-2a-trial-for-kidney-stone-prevention 2025-07-21T02:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-gut-bacteria-shows-promise-in-phase-1-2a-trial-for-kidney-stone-prevention 2025-07-21T02:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-evobody-bispecific-antibodies-show-promise-in-ovarian-cancer-by-targeting-vg9vd2-t-cells 2025-07-20T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-evobody-bispecific-antibodies-show-promise-in-ovarian-cancer-by-targeting-vg9vd2-t-cells 2025-07-20T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-panel-overwhelmingly-rejects-otsuka-s-ptsd-drug-combination-in-10-1-vote 2025-07-20T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-panel-overwhelmingly-rejects-otsuka-s-ptsd-drug-combination-in-10-1-vote 2025-07-20T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/positive-trial-shows-breastfeeding-safe-for-women-with-hr-positive-breast-cancer-after-treatment-interruption 2025-07-20T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positive-trial-shows-breastfeeding-safe-for-women-with-hr-positive-breast-cancer-after-treatment-interruption 2025-07-20T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/india-develops-indigenous-multi-stage-malaria-vaccine-adfalcivax-targeting-dual-parasite-protection 2025-07-20T17:24:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-develops-indigenous-multi-stage-malaria-vaccine-adfalcivax-targeting-dual-parasite-protection 2025-07-20T17:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/community-pharmacies-emerge-as-key-players-in-pharmacogenetic-testing-implementation 2025-07-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-pharmacies-emerge-as-key-players-in-pharmacogenetic-testing-implementation 2025-07-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-grants-interim-injunction-against-zydus-biosimilar-to-protect-nivolumab-patent-rights 2025-07-20T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-grants-interim-injunction-against-zydus-biosimilar-to-protect-nivolumab-patent-rights 2025-07-20T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/oncologists-prescribe-cancer-drugs-23-times-more-after-fda-accelerated-approval-than-traditional-approval 2025-07-20T13:20:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncologists-prescribe-cancer-drugs-23-times-more-after-fda-accelerated-approval-than-traditional-approval 2025-07-20T13:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/turkish-study-links-pfizer-covid-19-vaccine-to-corneal-structural-changes 2025-07-20T09:17:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turkish-study-links-pfizer-covid-19-vaccine-to-corneal-structural-changes 2025-07-20T09:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/onto-innovation-acquires-semilab-s-materials-analysis-business-for-545-million-to-expand-semiconductor-process-control-portfolio 2025-07-20T01:25:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onto-innovation-acquires-semilab-s-materials-analysis-business-for-545-million-to-expand-semiconductor-process-control-portfolio 2025-07-20T01:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/congressional-budget-office-warns-trump-s-proposed-nih-cuts-could-reduce-drug-approvals-by-4-5 2025-07-20T01:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/congressional-budget-office-warns-trump-s-proposed-nih-cuts-could-reduce-drug-approvals-by-4-5 2025-07-20T01:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/upc-ruling-protects-generic-drug-development-zentiva-wins-marketing-authorization-case-against-boehringer-ingelheim 2025-07-20T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-ruling-protects-generic-drug-development-zentiva-wins-marketing-authorization-case-against-boehringer-ingelheim 2025-07-20T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/blinatumomab-achieves-unprecedented-96-97-success-rate-in-pediatric-b-cell-all-treatment 2025-07-20T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinatumomab-achieves-unprecedented-96-97-success-rate-in-pediatric-b-cell-all-treatment 2025-07-20T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/b-c-government-reverses-funding-decision-for-rare-disease-treatment-after-expert-committee-resignations 2025-07-19T21:24:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-c-government-reverses-funding-decision-for-rare-disease-treatment-after-expert-committee-resignations 2025-07-19T21:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-achieve-first-in-human-in-vivo-car-t-therapy-using-genetically-modified-virus 2025-07-19T21:22:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-achieve-first-in-human-in-vivo-car-t-therapy-using-genetically-modified-virus 2025-07-19T21:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-analysis-reveals-unexpected-safety-signals-for-temozolomide-in-glioma-treatment 2025-07-19T21:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-analysis-reveals-unexpected-safety-signals-for-temozolomide-in-glioma-treatment 2025-07-19T21:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/cochlear-receives-fda-approval-for-world-s-first-smart-cochlear-implant-with-upgradeable-firmware 2025-07-19T21:21:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cochlear-receives-fda-approval-for-world-s-first-smart-cochlear-implant-with-upgradeable-firmware 2025-07-19T21:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-obesity-accelerates-biological-aging-in-young-adults-study-finds 2025-07-19T21:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-obesity-accelerates-biological-aging-in-young-adults-study-finds 2025-07-19T21:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/panjab-university-researchers-patent-magnetic-lignin-nano-constructs-for-advanced-3d-cancer-cell-culture 2025-07-19T16:59:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panjab-university-researchers-patent-magnetic-lignin-nano-constructs-for-advanced-3d-cancer-cell-culture 2025-07-19T16:59:10+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-advances-dostarlimab-in-phase-3-colon-cancer-trial-and-phase-2-endometrial-cancer-study 2025-07-19T16:58:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-advances-dostarlimab-in-phase-3-colon-cancer-trial-and-phase-2-endometrial-cancer-study 2025-07-19T16:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/tibsovo-listed-on-australian-pbs-offering-first-targeted-therapy-for-rare-bile-duct-cancer 2025-07-19T13:19:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tibsovo-listed-on-australian-pbs-offering-first-targeted-therapy-for-rare-bile-duct-cancer 2025-07-19T13:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/cd163-tumor-associated-macrophages-linked-to-improved-nivolumab-outcomes-in-metastatic-renal-cell-carcinoma 2025-07-19T13:19:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd163-tumor-associated-macrophages-linked-to-improved-nivolumab-outcomes-in-metastatic-renal-cell-carcinoma 2025-07-19T13:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-phase-3-data-positions-company-for-multi-billion-dollar-market-opportunity 2025-07-19T06:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-phase-3-data-positions-company-for-multi-billion-dollar-market-opportunity 2025-07-19T06:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/champions-oncology-appoints-rob-brainin-as-new-ceo-to-drive-data-platform-expansion 2025-07-19T05:21:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/champions-oncology-appoints-rob-brainin-as-new-ceo-to-drive-data-platform-expansion 2025-07-19T05:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reports-strong-q2-2025-results-with-kisqali-leading-64-growth-surge 2025-07-19T02:55:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-reports-strong-q2-2025-results-with-kisqali-leading-64-growth-surge 2025-07-19T02:55:52+00:00 hourly 0.9 https://trial.medpath.com/news/amphastar-pharmaceuticals-plans-to-quadruple-us-manufacturing-capacity-in-major-domestic-expansion 2025-07-19T01:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amphastar-pharmaceuticals-plans-to-quadruple-us-manufacturing-capacity-in-major-domestic-expansion 2025-07-19T01:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-osilodrostat-for-second-line-cushing-syndrome-treatment-as-pipeline-advances 2025-07-19T01:20:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-osilodrostat-for-second-line-cushing-syndrome-treatment-as-pipeline-advances 2025-07-19T01:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/nanopharmaceutics-completes-phase-ii-enrollment-for-triapine-combination-therapy-in-neuroendocrine-tumors 2025-07-19T01:18:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanopharmaceutics-completes-phase-ii-enrollment-for-triapine-combination-therapy-in-neuroendocrine-tumors 2025-07-19T01:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/nuwellis-terminates-reverse-hf-clinical-trial-to-refocus-on-outpatient-heart-failure-market 2025-07-18T21:30:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuwellis-terminates-reverse-hf-clinical-trial-to-refocus-on-outpatient-heart-failure-market 2025-07-18T21:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-develop-pan-coronavirus-vaccine-candidate-with-99-9-protection-against-multiple-variants 2025-07-18T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-develop-pan-coronavirus-vaccine-candidate-with-99-9-protection-against-multiple-variants 2025-07-18T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-exzolt-first-oral-treatment-for-northern-fowl-mites-in-poultry 2025-07-18T21:28:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-exzolt-first-oral-treatment-for-northern-fowl-mites-in-poultry 2025-07-18T21:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-chief-strategy-officer-ryan-richardson-to-step-down-after-seven-year-tenure 2025-07-18T21:28:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-chief-strategy-officer-ryan-richardson-to-step-down-after-seven-year-tenure 2025-07-18T21:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-guelph-develops-canada-s-first-mrna-bird-flu-vaccine-for-commercial-poultry 2025-07-18T21:26:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-guelph-develops-canada-s-first-mrna-bird-flu-vaccine-for-commercial-poultry 2025-07-18T21:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-wins-appeal-overturns-106-5-million-patent-infringement-verdict-in-heart-valve-case 2025-07-18T21:24:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-wins-appeal-overturns-106-5-million-patent-infringement-verdict-in-heart-valve-case 2025-07-18T21:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/extended-half-life-factor-viii-therapy-reduces-bleeding-episodes-and-injection-frequency-in-hemophilia-a-patients 2025-07-18T21:24:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-half-life-factor-viii-therapy-reduces-bleeding-episodes-and-injection-frequency-in-hemophilia-a-patients 2025-07-18T21:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-1-outperforms-standard-chemotherapy-in-reversing-cancer-gene-silencing 2025-07-18T21:22:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telomir-1-outperforms-standard-chemotherapy-in-reversing-cancer-gene-silencing 2025-07-18T21:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/emerging-dry-eye-therapies-show-promise-blood-serum-drops-and-neuromodulation-lead-innovation-pipeline 2025-07-18T17:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emerging-dry-eye-therapies-show-promise-blood-serum-drops-and-neuromodulation-lead-innovation-pipeline 2025-07-18T17:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-files-new-drug-submission-for-crexont-in-canada-following-successful-phase-3-trial 2025-07-18T17:28:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/knight-therapeutics-files-new-drug-submission-for-crexont-in-canada-following-successful-phase-3-trial 2025-07-18T17:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/ojjaara-shows-superior-anemia-control-in-myelofibrosis-achieving-67-transfusion-independence-rate 2025-07-18T17:28:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ojjaara-shows-superior-anemia-control-in-myelofibrosis-achieving-67-transfusion-independence-rate 2025-07-18T17:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/metastasis-directed-radiotherapy-shows-durable-disease-control-in-oligometastatic-renal-cell-carcinoma-without-systemic-therapy 2025-07-18T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metastasis-directed-radiotherapy-shows-durable-disease-control-in-oligometastatic-renal-cell-carcinoma-without-systemic-therapy 2025-07-18T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-pharmaceuticals-presents-patient-reported-data-on-diabetic-peripheral-neuropathic-pain-at-aspn-2025 2025-07-18T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexicon-pharmaceuticals-presents-patient-reported-data-on-diabetic-peripheral-neuropathic-pain-at-aspn-2025 2025-07-18T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/belzutifan-demonstrates-superior-quality-adjusted-survival-time-compared-to-everolimus-in-advanced-renal-cell-carcinoma 2025-07-18T17:26:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belzutifan-demonstrates-superior-quality-adjusted-survival-time-compared-to-everolimus-in-advanced-renal-cell-carcinoma 2025-07-18T17:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-advances-pcs6422-in-phase-2-breast-cancer-trial-with-7-million-funding-boost 2025-07-18T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/processa-pharmaceuticals-advances-pcs6422-in-phase-2-breast-cancer-trial-with-7-million-funding-boost 2025-07-18T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/filgrastim-biosimilars-demonstrate-15-million-cost-savings-potential-in-cancer-care 2025-07-18T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/filgrastim-biosimilars-demonstrate-15-million-cost-savings-potential-in-cancer-care 2025-07-18T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/aenova-expands-irish-facility-to-tackle-drug-bioavailability-challenge-with-advanced-spray-drying-technology 2025-07-18T17:24:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aenova-expands-irish-facility-to-tackle-drug-bioavailability-challenge-with-advanced-spray-drying-technology 2025-07-18T17:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-medicine-advances-cancer-pipeline-with-breakthrough-therapy-designations-and-clinical-trial-approvals 2025-07-18T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-medicine-advances-cancer-pipeline-with-breakthrough-therapy-designations-and-clinical-trial-approvals 2025-07-18T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-reblozyl-fails-primary-endpoint-in-phase-iii-myelofibrosis-trial-despite-secondary-benefits 2025-07-18T17:23:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-reblozyl-fails-primary-endpoint-in-phase-iii-myelofibrosis-trial-despite-secondary-benefits 2025-07-18T17:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-hidradenitis-suppurativa-shows-superior-response-to-adalimumab-over-infliximab-in-real-world-study 2025-07-18T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pediatric-hidradenitis-suppurativa-shows-superior-response-to-adalimumab-over-infliximab-in-real-world-study 2025-07-18T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-pharmaceuticals-lead-compound-shows-promise-in-reversing-cancer-gene-silencing 2025-07-18T13:23:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telomir-pharmaceuticals-lead-compound-shows-promise-in-reversing-cancer-gene-silencing 2025-07-18T13:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/abvc-biopharma-receives-150k-milestone-payment-advancing-botanical-cns-therapies-through-strategic-partnerships 2025-07-18T13:22:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abvc-biopharma-receives-150k-milestone-payment-advancing-botanical-cns-therapies-through-strategic-partnerships 2025-07-18T13:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-cancels-mrna-manufacturing-plant-in-japan-amid-declining-vaccine-demand-and-regulatory-uncertainty 2025-07-18T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-cancels-mrna-manufacturing-plant-in-japan-amid-declining-vaccine-demand-and-regulatory-uncertainty 2025-07-18T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-florida-researchers-develop-universal-mrna-cancer-vaccine-that-awakens-immune-system 2025-07-18T13:21:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-florida-researchers-develop-universal-mrna-cancer-vaccine-that-awakens-immune-system 2025-07-18T13:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/german-researchers-develop-gallium-complex-that-triggers-immunogenic-cell-death-to-combat-cancer-metastases 2025-07-18T13:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-researchers-develop-gallium-complex-that-triggers-immunogenic-cell-death-to-combat-cancer-metastases 2025-07-18T13:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/btk-inhibitors-challenge-traditional-ms-coverage-models-as-payers-seek-evidence-based-alternatives-to-step-therapy 2025-07-18T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/btk-inhibitors-challenge-traditional-ms-coverage-models-as-payers-seek-evidence-based-alternatives-to-step-therapy 2025-07-18T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/nuclear-waste-from-manhattan-project-transformed-into-breakthrough-cancer-treatment-at-oak-ridge 2025-07-18T09:15:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclear-waste-from-manhattan-project-transformed-into-breakthrough-cancer-treatment-at-oak-ridge 2025-07-18T09:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/4dmedical-advances-respiratory-imaging-technology-with-university-partnership-extension-and-ai-development-grant 2025-07-18T09:15:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4dmedical-advances-respiratory-imaging-technology-with-university-partnership-extension-and-ai-development-grant 2025-07-18T09:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/trogenix-strengthens-leadership-team-with-key-clinical-appointments-as-odysseus-platform-advances-toward-clinical-trials 2025-07-18T09:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trogenix-strengthens-leadership-team-with-key-clinical-appointments-as-odysseus-platform-advances-toward-clinical-trials 2025-07-18T09:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/deepqure-receives-mfds-approval-for-atrial-fibrillation-trial-of-novel-laparoscopic-renal-denervation-system 2025-07-18T09:14:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepqure-receives-mfds-approval-for-atrial-fibrillation-trial-of-novel-laparoscopic-renal-denervation-system 2025-07-18T09:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/biomedit-advances-first-in-class-probiotic-antibody-platform-with-18-4m-series-b-funding 2025-07-18T09:14:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomedit-advances-first-in-class-probiotic-antibody-platform-with-18-4m-series-b-funding 2025-07-18T09:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-pharmacovigilance-study-confirms-safety-of-ntc-s-fixed-dose-eye-drops-for-post-cataract-surgery 2025-07-18T09:14:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-pharmacovigilance-study-confirms-safety-of-ntc-s-fixed-dose-eye-drops-for-post-cataract-surgery 2025-07-18T09:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/type-1-diabetes-pipeline-shows-robust-growth-with-85-companies-developing-100-therapeutic-candidates 2025-07-18T05:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/type-1-diabetes-pipeline-shows-robust-growth-with-85-companies-developing-100-therapeutic-candidates 2025-07-18T05:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-advances-phase-3-study-of-etelcalcetide-for-pediatric-secondary-hyperparathyroidism 2025-07-18T05:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-advances-phase-3-study-of-etelcalcetide-for-pediatric-secondary-hyperparathyroidism 2025-07-18T05:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-combinations-transform-advanced-squamous-cell-anal-cancer-treatment-landscape 2025-07-18T03:55:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-combinations-transform-advanced-squamous-cell-anal-cancer-treatment-landscape 2025-07-18T03:55:16+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-reports-nine-month-efficacy-data-for-combined-sculptra-and-restylane-treatment-in-glp-1-associated-facial-volume-loss 2025-07-18T01:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-reports-nine-month-efficacy-data-for-combined-sculptra-and-restylane-treatment-in-glp-1-associated-facial-volume-loss 2025-07-18T01:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-boosters-reduce-hospitalization-risk-by-29-in-cancer-patients-large-multi-center-study-shows 2025-07-18T01:22:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-boosters-reduce-hospitalization-risk-by-29-in-cancer-patients-large-multi-center-study-shows 2025-07-18T01:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/british-columbia-restricts-sales-of-diabetes-drugs-tirzepatide-and-dulaglutide-to-combat-weight-loss-driven-shortages 2025-07-18T01:22:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/british-columbia-restricts-sales-of-diabetes-drugs-tirzepatide-and-dulaglutide-to-combat-weight-loss-driven-shortages 2025-07-18T01:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/eledon-pharmaceuticals-to-present-updated-phase-1b-kidney-transplant-data-for-tegoprubart-at-world-transplant-congress-2025 2025-07-18T01:22:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eledon-pharmaceuticals-to-present-updated-phase-1b-kidney-transplant-data-for-tegoprubart-at-world-transplant-congress-2025 2025-07-18T01:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/neurogen-biomarking-to-present-validation-data-for-at-home-alzheimer-s-blood-biomarker-test-at-aaic-2025 2025-07-18T01:21:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurogen-biomarking-to-present-validation-data-for-at-home-alzheimer-s-blood-biomarker-test-at-aaic-2025 2025-07-18T01:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-therapeutics-raises-ps3-25-million-and-secures-bond-amendment-to-advance-fap-dox-cancer-therapy 2025-07-18T01:21:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-therapeutics-raises-ps3-25-million-and-secures-bond-amendment-to-advance-fap-dox-cancer-therapy 2025-07-18T01:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-real-world-study-shows-comparable-remission-rates-between-etanercept-biosimilars-and-originator-in-rheumatoid-arthritis 2025-07-18T01:20:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-real-world-study-shows-comparable-remission-rates-between-etanercept-biosimilars-and-originator-in-rheumatoid-arthritis 2025-07-18T01:20:36+00:00 hourly 0.9 https://trial.medpath.com/news/nihr-pilots-just-in-time-clinical-trial-initiative-for-pancreatic-cancer-using-pembrolizumab-olaparib-combination 2025-07-18T01:20:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nihr-pilots-just-in-time-clinical-trial-initiative-for-pancreatic-cancer-using-pembrolizumab-olaparib-combination 2025-07-18T01:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expert-panel-calls-for-revision-of-menopausal-hormone-therapy-warning-labels 2025-07-18T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expert-panel-calls-for-revision-of-menopausal-hormone-therapy-warning-labels 2025-07-18T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/microbiome-signatures-in-blood-and-gut-emerge-as-promising-biomarkers-for-colorectal-cancer-detection 2025-07-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiome-signatures-in-blood-and-gut-emerge-as-promising-biomarkers-for-colorectal-cancer-detection 2025-07-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acute-ischemic-stroke-pipeline-shows-promise-with-25-therapies-in-development-and-recent-clinical-breakthroughs 2025-07-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acute-ischemic-stroke-pipeline-shows-promise-with-25-therapies-in-development-and-recent-clinical-breakthroughs 2025-07-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/multi-cancer-detection-blood-tests-enter-major-clinical-trial-across-virginia-and-missouri 2025-07-17T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-cancer-detection-blood-tests-enter-major-clinical-trial-across-virginia-and-missouri 2025-07-17T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-rejects-gsk-s-blenrep-combination-therapies-for-multiple-myeloma 2025-07-17T21:24:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-panel-rejects-gsk-s-blenrep-combination-therapies-for-multiple-myeloma 2025-07-17T21:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/robotic-assisted-aneurysm-embolization-achieves-94-technical-success-rate-in-six-month-follow-up-study 2025-07-17T21:22:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robotic-assisted-aneurysm-embolization-achieves-94-technical-success-rate-in-six-month-follow-up-study 2025-07-17T21:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/aspect-biosystems-bioprinted-adrenal-tissues-show-promise-for-primary-adrenal-insufficiency-treatment 2025-07-17T21:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspect-biosystems-bioprinted-adrenal-tissues-show-promise-for-primary-adrenal-insufficiency-treatment 2025-07-17T21:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-advances-troriluzole-in-phase-2-3-trial-for-treatment-resistant-ocd-as-pipeline-expands 2025-07-17T21:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-advances-troriluzole-in-phase-2-3-trial-for-treatment-resistant-ocd-as-pipeline-expands 2025-07-17T21:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-juul-e-cigarettes-for-continued-market-sale-after-multiyear-review 2025-07-17T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-juul-e-cigarettes-for-continued-market-sale-after-multiyear-review 2025-07-17T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-rectal-cancer-drug-metric-fails-to-predict-long-term-survival-tulane-study-finds 2025-07-17T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-rectal-cancer-drug-metric-fails-to-predict-long-term-survival-tulane-study-finds 2025-07-17T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/ambulatory-pharmacists-emerge-as-key-players-in-value-based-care-models-to-address-rising-drug-costs 2025-07-17T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ambulatory-pharmacists-emerge-as-key-players-in-value-based-care-models-to-address-rising-drug-costs 2025-07-17T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-recalls-bicillin-l-a-due-to-contamination-threatening-syphilis-treatment-amid-rising-congenital-cases 2025-07-17T17:38:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-recalls-bicillin-l-a-due-to-contamination-threatening-syphilis-treatment-amid-rising-congenital-cases 2025-07-17T17:38:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-ends-rare-pediatric-disease-designation-program-after-decade-of-mixed-results 2025-07-17T17:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-ends-rare-pediatric-disease-designation-program-after-decade-of-mixed-results 2025-07-17T17:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/citizens-petition-seeks-fda-accelerated-approval-for-nurown-stem-cell-therapy-in-als-based-on-survival-data 2025-07-17T17:35:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citizens-petition-seeks-fda-accelerated-approval-for-nurown-stem-cell-therapy-in-als-based-on-survival-data 2025-07-17T17:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/renovaro-s-engineered-dendritic-cell-therapy-achieves-81-7-tumor-reduction-in-pancreatic-cancer-models 2025-07-17T17:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovaro-s-engineered-dendritic-cell-therapy-achieves-81-7-tumor-reduction-in-pancreatic-cancer-models 2025-07-17T17:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/nanjing-leads-biolabs-soars-122-on-hong-kong-debut-following-hk-1-1-billion-ipo 2025-07-17T17:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanjing-leads-biolabs-soars-122-on-hong-kong-debut-following-hk-1-1-billion-ipo 2025-07-17T17:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-s-patent-landscape-transformation-supreme-court-ruling-reshapes-pharmaceutical-ip-strategy 2025-07-17T17:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-s-patent-landscape-transformation-supreme-court-ruling-reshapes-pharmaceutical-ip-strategy 2025-07-17T17:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/one-biosciences-secures-eur15-million-series-a-to-advance-ai-powered-single-cell-cancer-diagnostics-platform 2025-07-17T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-biosciences-secures-eur15-million-series-a-to-advance-ai-powered-single-cell-cancer-diagnostics-platform 2025-07-17T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/keros-therapeutics-initiates-phase-3-renew-trial-for-elritercept-in-myelodysplastic-syndromes-triggers-10m-takeda-milestone 2025-07-17T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keros-therapeutics-initiates-phase-3-renew-trial-for-elritercept-in-myelodysplastic-syndromes-triggers-10m-takeda-milestone 2025-07-17T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/seaport-therapeutics-initiates-phase-2b-trial-of-novel-oral-antidepressant-glyphallo 2025-07-17T17:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seaport-therapeutics-initiates-phase-2b-trial-of-novel-oral-antidepressant-glyphallo 2025-07-17T17:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/moma-therapeutics-initiates-first-in-human-trial-of-werner-helicase-inhibitor-moma-341-for-msi-h-solid-tumors 2025-07-17T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moma-therapeutics-initiates-first-in-human-trial-of-werner-helicase-inhibitor-moma-341-for-msi-h-solid-tumors 2025-07-17T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-reports-promising-60-response-rate-in-pancreatic-cancer-trial-with-certepetide 2025-07-17T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-therapeutics-reports-promising-60-response-rate-in-pancreatic-cancer-trial-with-certepetide 2025-07-17T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/harrow-secures-exclusive-us-rights-to-samsung-bioepis-ophthalmology-biosimilars-portfolio 2025-07-17T17:27:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harrow-secures-exclusive-us-rights-to-samsung-bioepis-ophthalmology-biosimilars-portfolio 2025-07-17T17:27:56+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-acquires-bridge-health-biotech-to-strengthen-givastomig-bispecific-antibody-development 2025-07-17T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-mab-acquires-bridge-health-biotech-to-strengthen-givastomig-bispecific-antibody-development 2025-07-17T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/regen-biopharma-prepares-phase-i-trial-for-hemaxellerate-stem-cell-therapy-targeting-severe-aplastic-anemia 2025-07-17T17:27:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regen-biopharma-prepares-phase-i-trial-for-hemaxellerate-stem-cell-therapy-targeting-severe-aplastic-anemia 2025-07-17T17:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-s-dm199-shows-promising-blood-pressure-reduction-in-phase-2-preeclampsia-trial 2025-07-17T17:27:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamedica-s-dm199-shows-promising-blood-pressure-reduction-in-phase-2-preeclampsia-trial 2025-07-17T17:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/cube-biotech-appoints-michael-bencak-as-new-ceo-to-drive-global-expansion-in-protein-technologies 2025-07-17T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cube-biotech-appoints-michael-bencak-as-new-ceo-to-drive-global-expansion-in-protein-technologies 2025-07-17T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/news/uromems-receives-fda-and-ansm-clearance-for-pivotal-trial-of-smart-artificial-urinary-sphincter 2025-07-17T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uromems-receives-fda-and-ansm-clearance-for-pivotal-trial-of-smart-artificial-urinary-sphincter 2025-07-17T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/fifty1-labs-partners-with-biospark-ai-to-accelerate-drug-repurposing-through-advanced-literature-mining 2025-07-17T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fifty1-labs-partners-with-biospark-ai-to-accelerate-drug-repurposing-through-advanced-literature-mining 2025-07-17T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-appoints-roche-veteran-adriano-treve-as-strategic-advisor-ahead-of-phase-3-aml-trial-data 2025-07-17T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moleculin-appoints-roche-veteran-adriano-treve-as-strategic-advisor-ahead-of-phase-3-aml-trial-data 2025-07-17T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-appoints-telitacicept-development-expert-dr-qing-zuraw-as-chief-development-officer 2025-07-17T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vor-bio-appoints-telitacicept-development-expert-dr-qing-zuraw-as-chief-development-officer 2025-07-17T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/congressional-lawmakers-push-for-fast-track-approval-of-antiparasitic-treatments-as-new-world-screwworm-threat-approaches-u-s-border 2025-07-17T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/congressional-lawmakers-push-for-fast-track-approval-of-antiparasitic-treatments-as-new-world-screwworm-threat-approaches-u-s-border 2025-07-17T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/saluda-medical-launches-eva-sensing-technology-for-personalized-spinal-cord-stimulation-in-u-s 2025-07-17T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saluda-medical-launches-eva-sensing-technology-for-personalized-spinal-cord-stimulation-in-u-s 2025-07-17T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/trivarx-advances-ai-powered-depression-screening-with-veterans-affairs-clinical-trial 2025-07-17T17:23:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trivarx-advances-ai-powered-depression-screening-with-veterans-affairs-clinical-trial 2025-07-17T17:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-pfizer-launch-direct-to-patient-eliquis-program-with-40-price-discount 2025-07-17T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-pfizer-launch-direct-to-patient-eliquis-program-with-40-price-discount 2025-07-17T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/velocity-clinical-research-partners-with-palantir-to-automate-clinical-trial-payment-reconciliation-using-ai 2025-07-17T17:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/velocity-clinical-research-partners-with-palantir-to-automate-clinical-trial-payment-reconciliation-using-ai 2025-07-17T17:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/10x-genomics-partners-with-singapore-institute-to-launch-ai-driven-cancer-drug-discovery-study 2025-07-17T17:22:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10x-genomics-partners-with-singapore-institute-to-launch-ai-driven-cancer-drug-discovery-study 2025-07-17T17:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/ginkgo-bioworks-launches-automated-adme-profiling-service-to-accelerate-small-molecule-drug-discovery 2025-07-17T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ginkgo-bioworks-launches-automated-adme-profiling-service-to-accelerate-small-molecule-drug-discovery 2025-07-17T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/organoid-technology-advances-diabetes-research-with-sophisticated-3d-models-and-therapeutic-applications 2025-07-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organoid-technology-advances-diabetes-research-with-sophisticated-3d-models-and-therapeutic-applications 2025-07-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bedtime-blood-pressure-medication-dosing-shows-superior-nighttime-control-in-chinese-trial 2025-07-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bedtime-blood-pressure-medication-dosing-shows-superior-nighttime-control-in-chinese-trial 2025-07-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designations-for-fragile-x-syndrome-and-radiation-induced-maculopathy-treatments 2025-07-17T14:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designations-for-fragile-x-syndrome-and-radiation-induced-maculopathy-treatments 2025-07-17T14:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/bird-foundation-approves-additional-funding-for-itol-102-type-1-diabetes-cell-therapy-following-fda-pre-ind-meeting 2025-07-17T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bird-foundation-approves-additional-funding-for-itol-102-type-1-diabetes-cell-therapy-following-fda-pre-ind-meeting 2025-07-17T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/jaya-biosciences-secures-key-asian-patents-for-novel-alzheimer-s-gene-therapy-targeting-lysosomal-enzyme-defects 2025-07-17T13:29:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaya-biosciences-secures-key-asian-patents-for-novel-alzheimer-s-gene-therapy-targeting-lysosomal-enzyme-defects 2025-07-17T13:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/european-court-cancels-biogen-s-extended-market-exclusivity-for-multiple-sclerosis-drug-tecfidera 2025-07-17T13:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-court-cancels-biogen-s-extended-market-exclusivity-for-multiple-sclerosis-drug-tecfidera 2025-07-17T13:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-secures-24-3m-funding-as-idefirix-sales-surge-76-in-q2-2025 2025-07-17T13:27:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-secures-24-3m-funding-as-idefirix-sales-surge-76-in-q2-2025 2025-07-17T13:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/mmj-international-ceo-alleges-dea-obstruction-of-fda-authorized-cannabis-research-for-neurological-diseases 2025-07-17T13:27:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mmj-international-ceo-alleges-dea-obstruction-of-fda-authorized-cannabis-research-for-neurological-diseases 2025-07-17T13:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/newer-antiseizure-medications-show-improved-safety-profile-during-pregnancy 2025-07-17T10:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newer-antiseizure-medications-show-improved-safety-profile-during-pregnancy 2025-07-17T10:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/nanochon-receives-health-canada-approval-for-first-in-human-trial-of-3d-printed-knee-cartilage-implant 2025-07-17T09:25:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanochon-receives-health-canada-approval-for-first-in-human-trial-of-3d-printed-knee-cartilage-implant 2025-07-17T09:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-proves-safe-and-effective-for-octogenarians-with-b-cell-lymphoma 2025-07-17T09:21:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-proves-safe-and-effective-for-octogenarians-with-b-cell-lymphoma 2025-07-17T09:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-pharmaceuticals-launches-first-in-class-acne-treatment-winlevi-in-southeast-asia 2025-07-17T09:19:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-pharmaceuticals-launches-first-in-class-acne-treatment-winlevi-in-southeast-asia 2025-07-17T09:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-implements-400-million-cost-cutting-plan-amid-regulatory-challenges-for-gene-therapy 2025-07-17T05:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-therapeutics-implements-400-million-cost-cutting-plan-amid-regulatory-challenges-for-gene-therapy 2025-07-17T05:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/ihc-testing-enables-rapid-tp53-mutation-detection-in-mds-and-aml-patients 2025-07-17T05:18:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ihc-testing-enables-rapid-tp53-mutation-detection-in-mds-and-aml-patients 2025-07-17T05:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/aav-gene-therapy-pipeline-expands-with-180-companies-developing-250-treatments-despite-recent-setbacks 2025-07-17T03:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aav-gene-therapy-pipeline-expands-with-180-companies-developing-250-treatments-despite-recent-setbacks 2025-07-17T03:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-industry-adapts-strategic-drug-development-amid-funding-crisis-and-regulatory-uncertainty 2025-07-17T02:57:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-industry-adapts-strategic-drug-development-amid-funding-crisis-and-regulatory-uncertainty 2025-07-17T02:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-implements-major-workforce-reduction-and-policy-changes-amid-regulatory-overhaul 2025-07-17T02:56:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-implements-major-workforce-reduction-and-policy-changes-amid-regulatory-overhaul 2025-07-17T02:56:36+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-strengthens-neuroscience-portfolio-with-14-6-billion-intra-cellular-acquisition 2025-07-17T01:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-strengthens-neuroscience-portfolio-with-14-6-billion-intra-cellular-acquisition 2025-07-17T01:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/openevidence-raises-210-million-series-b-to-expand-ai-powered-medical-research-platform-for-physicians 2025-07-17T01:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/openevidence-raises-210-million-series-b-to-expand-ai-powered-medical-research-platform-for-physicians 2025-07-17T01:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/yale-researchers-engineer-novel-antibody-rna-therapy-platform-for-treatment-resistant-cancers 2025-07-17T01:20:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-researchers-engineer-novel-antibody-rna-therapy-platform-for-treatment-resistant-cancers 2025-07-17T01:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/eight-healthy-babies-born-in-britain-using-three-person-dna-technique-to-prevent-mitochondrial-disease 2025-07-17T01:19:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-healthy-babies-born-in-britain-using-three-person-dna-technique-to-prevent-mitochondrial-disease 2025-07-17T01:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/csir-launches-nationwide-phenome-india-health-cohort-study-to-develop-personalized-disease-risk-predictions 2025-07-17T01:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csir-launches-nationwide-phenome-india-health-cohort-study-to-develop-personalized-disease-risk-predictions 2025-07-17T01:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/22nd-century-group-expands-vln-reduced-nicotine-cigarette-partnerships-ahead-of-fda-mandate 2025-07-17T01:18:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/22nd-century-group-expands-vln-reduced-nicotine-cigarette-partnerships-ahead-of-fda-mandate 2025-07-17T01:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/overture-orthopaedics-launches-overtureti-knee-resurfacing-system-for-early-osteoarthritis-treatment 2025-07-17T01:17:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/overture-orthopaedics-launches-overtureti-knee-resurfacing-system-for-early-osteoarthritis-treatment 2025-07-17T01:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/idt-launches-hdr-enhancer-protein-to-boost-crispr-gene-editing-efficiency-in-therapeutic-applications 2025-07-17T01:16:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idt-launches-hdr-enhancer-protein-to-boost-crispr-gene-editing-efficiency-in-therapeutic-applications 2025-07-17T01:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/nexgel-expands-stada-partnership-with-1-million-investment-for-digestive-enzyme-and-scar-treatment-products 2025-07-17T01:16:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexgel-expands-stada-partnership-with-1-million-investment-for-digestive-enzyme-and-scar-treatment-products 2025-07-17T01:16:29+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-new-payment-structure-for-skin-substitutes-regenerative-medicine-companies-welcome-reform 2025-07-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-proposes-new-payment-structure-for-skin-substitutes-regenerative-medicine-companies-welcome-reform 2025-07-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dogs-demonstrate-high-accuracy-in-detecting-parkinson-s-disease-through-scent-analysis 2025-07-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dogs-demonstrate-high-accuracy-in-detecting-parkinson-s-disease-through-scent-analysis 2025-07-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wehi-partners-with-parkinson-s-research-foundation-to-accelerate-drug-discovery-for-world-s-fastest-growing-neurological-condition 2025-07-16T23:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wehi-partners-with-parkinson-s-research-foundation-to-accelerate-drug-discovery-for-world-s-fastest-growing-neurological-condition 2025-07-16T23:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/endtb-q-trial-reveals-need-for-personalized-treatment-in-drug-resistant-tuberculosis 2025-07-16T21:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endtb-q-trial-reveals-need-for-personalized-treatment-in-drug-resistant-tuberculosis 2025-07-16T21:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-awards-5-million-to-nagasaki-university-for-ai-powered-nanoball-mrna-vaccine-platform-against-disease-x 2025-07-16T21:31:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-awards-5-million-to-nagasaki-university-for-ai-powered-nanoball-mrna-vaccine-platform-against-disease-x 2025-07-16T21:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/neocast-liquid-embolic-shows-promise-for-pain-free-treatment-of-chronic-subdural-hematoma 2025-07-16T21:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neocast-liquid-embolic-shows-promise-for-pain-free-treatment-of-chronic-subdural-hematoma 2025-07-16T21:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-invalidates-shockwave-medical-s-intravascular-lithotripsy-patent-in-precedential-ruling 2025-07-16T21:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-invalidates-shockwave-medical-s-intravascular-lithotripsy-patent-in-precedential-ruling 2025-07-16T21:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-secures-1-9m-non-dilutive-funding-following-positive-phase-2-results-and-fda-fast-track-designation 2025-07-16T21:25:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/okyo-pharma-secures-1-9m-non-dilutive-funding-following-positive-phase-2-results-and-fda-fast-track-designation 2025-07-16T21:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-partners-with-cspc-for-ai-driven-drug-discovery-platform-to-develop-novel-oral-therapies 2025-07-16T21:25:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-partners-with-cspc-for-ai-driven-drug-discovery-platform-to-develop-novel-oral-therapies 2025-07-16T21:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-intellia-advance-crispr-gene-therapy-trial-for-hemophilia-b-treatment 2025-07-16T21:25:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-and-intellia-advance-crispr-gene-therapy-trial-for-hemophilia-b-treatment 2025-07-16T21:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/quetzal-therapeutics-launches-with-50-million-to-advance-oral-arsenic-trioxide-therapy-for-acute-promyelocytic-leukemia 2025-07-16T21:24:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quetzal-therapeutics-launches-with-50-million-to-advance-oral-arsenic-trioxide-therapy-for-acute-promyelocytic-leukemia 2025-07-16T21:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/msbai-secures-2m-dod-phase-iii-contract-for-guru-generation-2-ai-platform 2025-07-16T21:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msbai-secures-2m-dod-phase-iii-contract-for-guru-generation-2-ai-platform 2025-07-16T21:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reviewers-flag-discordant-results-for-rexulti-sertraline-ptsd-treatment-ahead-of-advisory-committee-meeting 2025-07-16T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reviewers-flag-discordant-results-for-rexulti-sertraline-ptsd-treatment-ahead-of-advisory-committee-meeting 2025-07-16T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-acquires-sanofi-s-new-jersey-manufacturing-site-to-expand-u-s-sterile-drug-production 2025-07-16T17:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-acquires-sanofi-s-new-jersey-manufacturing-site-to-expand-u-s-sterile-drug-production 2025-07-16T17:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/polypid-unveils-60-day-glp-1-delivery-platform-to-transform-diabetes-and-weight-management-treatment 2025-07-16T17:34:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polypid-unveils-60-day-glp-1-delivery-platform-to-transform-diabetes-and-weight-management-treatment 2025-07-16T17:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/qualigen-therapeutics-secures-global-patent-protection-for-cancer-drug-qn-302-across-25-countries 2025-07-16T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qualigen-therapeutics-secures-global-patent-protection-for-cancer-drug-qn-302-across-25-countries 2025-07-16T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/miplyffa-shows-5-year-sustained-efficacy-in-rare-npc-disease-extension-study 2025-07-16T17:29:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miplyffa-shows-5-year-sustained-efficacy-in-rare-npc-disease-extension-study 2025-07-16T17:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/voyager-therapeutics-advances-novel-apoe4-gene-therapy-for-alzheimer-s-disease-using-iv-delivered-tracer-platform 2025-07-16T17:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voyager-therapeutics-advances-novel-apoe4-gene-therapy-for-alzheimer-s-disease-using-iv-delivered-tracer-platform 2025-07-16T17:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/cystic-fibrosis-foundation-commits-additional-24-million-to-prime-medicine-for-gene-editing-therapy-development 2025-07-16T17:28:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cystic-fibrosis-foundation-commits-additional-24-million-to-prime-medicine-for-gene-editing-therapy-development 2025-07-16T17:28:43+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-leap-receives-fda-ind-clearance-for-first-in-class-oral-il-2-modulator-gl-il2-138 2025-07-16T17:28:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-leap-receives-fda-ind-clearance-for-first-in-class-oral-il-2-modulator-gl-il2-138 2025-07-16T17:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/cue-101-combination-therapy-achieves-50-response-rate-in-hpv-head-and-neck-cancer-trial 2025-07-16T17:27:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cue-101-combination-therapy-achieves-50-response-rate-in-hpv-head-and-neck-cancer-trial 2025-07-16T17:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-raises-2025-outlook-as-oncology-portfolio-drives-24-growth 2025-07-16T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-raises-2025-outlook-as-oncology-portfolio-drives-24-growth 2025-07-16T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reviewers-question-efficacy-of-otsuka-s-brexpiprazole-zoloft-combination-for-ptsd-treatment 2025-07-16T17:27:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reviewers-question-efficacy-of-otsuka-s-brexpiprazole-zoloft-combination-for-ptsd-treatment 2025-07-16T17:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/endeavor-biomedicines-receives-dual-orphan-drug-designation-for-taladegib-in-idiopathic-pulmonary-fibrosis 2025-07-16T17:26:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endeavor-biomedicines-receives-dual-orphan-drug-designation-for-taladegib-in-idiopathic-pulmonary-fibrosis 2025-07-16T17:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/logicare3pl-secures-exclusive-distribution-partnership-for-chirhostim-diagnostic-product 2025-07-16T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/logicare3pl-secures-exclusive-distribution-partnership-for-chirhostim-diagnostic-product 2025-07-16T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/stargardt-disease-pipeline-shows-promising-progress-with-multiple-gene-therapies-advancing-to-late-stage-trials 2025-07-16T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stargardt-disease-pipeline-shows-promising-progress-with-multiple-gene-therapies-advancing-to-late-stage-trials 2025-07-16T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-biosimilar-application-for-bat2506-proposed-golimumab-alternative 2025-07-16T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-biosimilar-application-for-bat2506-proposed-golimumab-alternative 2025-07-16T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/sandboxaq-and-ioncologi-partner-to-develop-ai-driven-mrna-vaccine-for-glioblastoma 2025-07-16T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandboxaq-and-ioncologi-partner-to-develop-ai-driven-mrna-vaccine-for-glioblastoma 2025-07-16T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-receives-fda-510-k-clearance-for-ecg-low-ef-software-to-detect-heart-failure-risk 2025-07-16T17:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-receives-fda-510-k-clearance-for-ecg-low-ef-software-to-detect-heart-failure-risk 2025-07-16T17:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/piccolo-medical-receives-fda-clearance-for-next-generation-smartpicc-technology 2025-07-16T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piccolo-medical-receives-fda-clearance-for-next-generation-smartpicc-technology 2025-07-16T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-cincinnati-launches-phase-2-trial-of-novel-endocannabinoid-enhancing-drug-for-multiple-sclerosis-spasticity 2025-07-16T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-cincinnati-launches-phase-2-trial-of-novel-endocannabinoid-enhancing-drug-for-multiple-sclerosis-spasticity 2025-07-16T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-initiates-pele-clinical-trial-for-onyx-liquid-embolic-system-in-peripheral-arterial-hemorrhage 2025-07-16T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-initiates-pele-clinical-trial-for-onyx-liquid-embolic-system-in-peripheral-arterial-hemorrhage 2025-07-16T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/msc-derived-extracellular-vesicles-show-promise-as-cell-free-therapeutics-across-multiple-disease-areas 2025-07-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msc-derived-extracellular-vesicles-show-promise-as-cell-free-therapeutics-across-multiple-disease-areas 2025-07-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cms-launches-multi-state-payment-model-to-expand-access-to-sickle-cell-gene-therapies 2025-07-16T13:29:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-launches-multi-state-payment-model-to-expand-access-to-sickle-cell-gene-therapies 2025-07-16T13:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/sprim-pro-and-obviohealth-expand-partnership-to-accelerate-digital-clinical-trial-innovation 2025-07-16T13:28:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sprim-pro-and-obviohealth-expand-partnership-to-accelerate-digital-clinical-trial-innovation 2025-07-16T13:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/ibi343-shows-promising-efficacy-in-cldn18-2-positive-gastric-cancer-with-improved-safety-profile 2025-07-16T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibi343-shows-promising-efficacy-in-cldn18-2-positive-gastric-cancer-with-improved-safety-profile 2025-07-16T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/australian-companies-form-strategic-alliance-to-boost-advanced-therapy-manufacturing-capacity 2025-07-16T13:26:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-companies-form-strategic-alliance-to-boost-advanced-therapy-manufacturing-capacity 2025-07-16T13:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/uk-digital-health-platform-numan-raises-60m-to-expand-into-women-s-health 2025-07-16T13:26:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-digital-health-platform-numan-raises-60m-to-expand-into-women-s-health 2025-07-16T13:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/atricure-completes-enrollment-in-landmark-6500-patient-leaaps-trial-for-stroke-prevention 2025-07-16T13:25:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atricure-completes-enrollment-in-landmark-6500-patient-leaaps-trial-for-stroke-prevention 2025-07-16T13:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharm-acquires-lanova-medicines-for-950m-expanding-innovative-drug-pipeline 2025-07-16T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharm-acquires-lanova-medicines-for-950m-expanding-innovative-drug-pipeline 2025-07-16T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/stelara-biosimilars-capture-market-share-as-j-j-s-blockbuster-drug-faces-33-7-sales-decline 2025-07-16T13:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stelara-biosimilars-capture-market-share-as-j-j-s-blockbuster-drug-faces-33-7-sales-decline 2025-07-16T13:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/ps17-9-million-wellcome-grant-funds-major-initiative-to-combat-deadly-fungal-infections 2025-07-16T13:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ps17-9-million-wellcome-grant-funds-major-initiative-to-combat-deadly-fungal-infections 2025-07-16T13:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/apple-airpods-pro-2-receive-fda-clearance-as-over-the-counter-hearing-aids 2025-07-16T13:22:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apple-airpods-pro-2-receive-fda-clearance-as-over-the-counter-hearing-aids 2025-07-16T13:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-sar446597-gene-therapy-receives-fda-fast-track-designation-for-geographic-atrophy-treatment 2025-07-16T13:22:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-sar446597-gene-therapy-receives-fda-fast-track-designation-for-geographic-atrophy-treatment 2025-07-16T13:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/icon-leads-phase-1-clinical-trial-performance-with-highest-sponsor-satisfaction-score 2025-07-16T13:21:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icon-leads-phase-1-clinical-trial-performance-with-highest-sponsor-satisfaction-score 2025-07-16T13:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-diabetic-retinopathy-screening-achieves-99-accuracy-and-expands-to-pharmacy-networks 2025-07-16T10:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-diabetic-retinopathy-screening-achieves-99-accuracy-and-expands-to-pharmacy-networks 2025-07-16T10:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/nci-initiates-4-8-million-clinical-trial-of-senhwa-s-first-in-class-cancer-drug-cx-5461 2025-07-16T09:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nci-initiates-4-8-million-clinical-trial-of-senhwa-s-first-in-class-cancer-drug-cx-5461 2025-07-16T09:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/4moving-biotech-initiates-phase-2a-trial-of-first-in-class-glp-1-therapy-for-knee-osteoarthritis 2025-07-16T09:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4moving-biotech-initiates-phase-2a-trial-of-first-in-class-glp-1-therapy-for-knee-osteoarthritis 2025-07-16T09:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-anselamimab-fails-primary-endpoint-in-phase-iii-al-amyloidosis-trial-shows-promise-in-patient-subgroup 2025-07-16T09:15:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-anselamimab-fails-primary-endpoint-in-phase-iii-al-amyloidosis-trial-shows-promise-in-patient-subgroup 2025-07-16T09:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/phase-scientific-secures-exclusive-u-s-distribution-rights-for-febridx-rapid-respiratory-infection-test 2025-07-16T09:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-scientific-secures-exclusive-u-s-distribution-rights-for-febridx-rapid-respiratory-infection-test 2025-07-16T09:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/pragmatic-clinical-trials-bridge-gap-between-research-and-real-world-healthcare-practice 2025-07-16T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pragmatic-clinical-trials-bridge-gap-between-research-and-real-world-healthcare-practice 2025-07-16T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/mcmaster-study-identifies-most-effective-treatments-for-chronic-hives-through-comprehensive-meta-analysis 2025-07-16T05:27:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mcmaster-study-identifies-most-effective-treatments-for-chronic-hives-through-comprehensive-meta-analysis 2025-07-16T05:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letters-to-seven-companies-marketing-illegal-opioid-alternative-products-containing-7-hydroxymitragynine 2025-07-16T05:22:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letters-to-seven-companies-marketing-illegal-opioid-alternative-products-containing-7-hydroxymitragynine 2025-07-16T05:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/who-includes-arkbio-s-ziresovir-in-pediatric-rsv-drug-priority-list-marking-first-chinese-anti-rsv-drug-recognition 2025-07-16T05:21:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-includes-arkbio-s-ziresovir-in-pediatric-rsv-drug-priority-list-marking-first-chinese-anti-rsv-drug-recognition 2025-07-16T05:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/btx-a51-shows-promise-in-relapsed-refractory-aml-with-notable-activity-in-runx1-mutated-patients 2025-07-16T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/btx-a51-shows-promise-in-relapsed-refractory-aml-with-notable-activity-in-runx1-mutated-patients 2025-07-16T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-calls-for-standardized-reflexive-biomarker-testing-to-address-treatment-delays-in-lung-cancer 2025-07-16T02:55:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-calls-for-standardized-reflexive-biomarker-testing-to-address-treatment-delays-in-lung-cancer 2025-07-16T02:55:55+00:00 hourly 0.9 https://trial.medpath.com/news/immorta-bio-advances-senolytic-immunotherapy-senovax-toward-phase-i-iia-trial-in-advanced-nsclc 2025-07-16T01:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immorta-bio-advances-senolytic-immunotherapy-senovax-toward-phase-i-iia-trial-in-advanced-nsclc 2025-07-16T01:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-pharma-acquires-mod3-pharma-s-clinical-trial-manufacturing-capabilities-to-strengthen-early-phase-drug-development-services 2025-07-16T01:19:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-pharma-acquires-mod3-pharma-s-clinical-trial-manufacturing-capabilities-to-strengthen-early-phase-drug-development-services 2025-07-16T01:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-licenses-pkmyt1-inhibitor-lunresertib-to-debiopharm-in-267m-deal 2025-07-16T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repare-therapeutics-licenses-pkmyt1-inhibitor-lunresertib-to-debiopharm-in-267m-deal 2025-07-16T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/compremium-launches-first-in-human-study-of-non-invasive-thyroid-cancer-diagnostic-device 2025-07-16T01:19:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compremium-launches-first-in-human-study-of-non-invasive-thyroid-cancer-diagnostic-device 2025-07-16T01:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-whoop-over-unapproved-blood-pressure-feature 2025-07-16T01:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letter-to-whoop-over-unapproved-blood-pressure-feature 2025-07-16T01:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/omniscope-pioneers-immune-profiling-breakthrough-for-personalized-pediatric-cancer-therapy 2025-07-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omniscope-pioneers-immune-profiling-breakthrough-for-personalized-pediatric-cancer-therapy 2025-07-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-votes-against-gsk-s-blenrep-for-multiple-myeloma-over-eye-safety-concerns 2025-07-15T21:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-panel-votes-against-gsk-s-blenrep-for-multiple-myeloma-over-eye-safety-concerns 2025-07-15T21:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/csl-consolidates-r-d-operations-to-six-global-hubs-in-strategic-shift-toward-external-partnerships 2025-07-15T21:23:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-consolidates-r-d-operations-to-six-global-hubs-in-strategic-shift-toward-external-partnerships 2025-07-15T21:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-secures-patent-extension-for-gedatolisib-through-2042-strengthening-breast-cancer-drug-portfolio 2025-07-15T21:23:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celcuity-secures-patent-extension-for-gedatolisib-through-2042-strengthening-breast-cancer-drug-portfolio 2025-07-15T21:23:10+00:00 hourly 0.9 https://trial.medpath.com/news/bioaffinity-technologies-secures-international-patents-for-cypath-lung-cancer-diagnostic-in-china-and-canada 2025-07-15T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaffinity-technologies-secures-international-patents-for-cypath-lung-cancer-diagnostic-in-china-and-canada 2025-07-15T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-pharmaceutical-industry-faces-patent-suspension-threat-amid-u-s-trade-tensions 2025-07-15T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-pharmaceutical-industry-faces-patent-suspension-threat-amid-u-s-trade-tensions 2025-07-15T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-halol-plant-fails-another-fda-inspection-over-contamination-concerns 2025-07-15T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-halol-plant-fails-another-fda-inspection-over-contamination-concerns 2025-07-15T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-raises-eye-safety-concerns-for-gsk-s-blenrep-ahead-of-advisory-committee-review 2025-07-15T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-raises-eye-safety-concerns-for-gsk-s-blenrep-ahead-of-advisory-committee-review 2025-07-15T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/egetis-therapeutics-advances-toward-us-nda-submission-for-tiratricol-following-fda-breakthrough-therapy-designation 2025-07-15T21:21:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egetis-therapeutics-advances-toward-us-nda-submission-for-tiratricol-following-fda-breakthrough-therapy-designation 2025-07-15T21:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/evestia-clinical-merges-with-atlantic-research-group-to-create-global-specialist-cro 2025-07-15T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evestia-clinical-merges-with-atlantic-research-group-to-create-global-specialist-cro 2025-07-15T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/taxis-pharmaceuticals-receives-fda-qidp-designation-for-txa14007-efflux-pump-inhibitor-to-combat-antibiotic-resistant-pneumonia 2025-07-15T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taxis-pharmaceuticals-receives-fda-qidp-designation-for-txa14007-efflux-pump-inhibitor-to-combat-antibiotic-resistant-pneumonia 2025-07-15T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-kirsty-as-first-interchangeable-rapid-acting-insulin-aspart-biosimilar 2025-07-15T21:19:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-kirsty-as-first-interchangeable-rapid-acting-insulin-aspart-biosimilar 2025-07-15T21:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-shows-anti-aging-properties-in-preclinical-study-extending-cellular-lifespan-by-50 2025-07-15T21:18:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-shows-anti-aging-properties-in-preclinical-study-extending-cellular-lifespan-by-50 2025-07-15T21:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/aatec-medical-partners-with-northway-biotech-to-scale-atl-105-production-for-non-cf-bronchiectasis-treatment 2025-07-15T17:37:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aatec-medical-partners-with-northway-biotech-to-scale-atl-105-production-for-non-cf-bronchiectasis-treatment 2025-07-15T17:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-names-corleen-roche-as-cfo-during-commercial-launch-of-first-fda-approved-til-therapy 2025-07-15T17:37:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-names-corleen-roche-as-cfo-during-commercial-launch-of-first-fda-approved-til-therapy 2025-07-15T17:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-receives-fda-approval-for-generic-celecoxib-capsules-in-multiple-strengths 2025-07-15T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-receives-fda-approval-for-generic-celecoxib-capsules-in-multiple-strengths 2025-07-15T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-study-shows-stem-cell-therapy-enhances-immune-recovery-in-cats-with-coronavirus-offering-insights-for-long-covid-treatment 2025-07-15T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-study-shows-stem-cell-therapy-enhances-immune-recovery-in-cats-with-coronavirus-offering-insights-for-long-covid-treatment 2025-07-15T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/c-mo-medical-solutions-achieves-iso-13485-certification-for-ai-powered-cough-monitoring-technology 2025-07-15T17:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-mo-medical-solutions-achieves-iso-13485-certification-for-ai-powered-cough-monitoring-technology 2025-07-15T17:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-secures-composition-of-matter-patent-for-certepetide-through-2040 2025-07-15T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-therapeutics-secures-composition-of-matter-patent-for-certepetide-through-2040 2025-07-15T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/merakris-therapeutics-mtx-001-selected-as-finalist-for-advanced-wound-care-innovation-showcase 2025-07-15T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merakris-therapeutics-mtx-001-selected-as-finalist-for-advanced-wound-care-innovation-showcase 2025-07-15T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-acquires-lanova-medicines-for-951-million-targeting-pd-1xvegf-cancer-therapies 2025-07-15T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharmaceutical-acquires-lanova-medicines-for-951-million-targeting-pd-1xvegf-cancer-therapies 2025-07-15T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/medera-treats-first-patient-in-groundbreaking-gene-therapy-trial-for-duchenne-muscular-dystrophy-heart-failure 2025-07-15T17:28:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medera-treats-first-patient-in-groundbreaking-gene-therapy-trial-for-duchenne-muscular-dystrophy-heart-failure 2025-07-15T17:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/tdm-guided-ustekinumab-optimization-shows-superior-long-term-efficacy-in-crohn-s-disease-maintenance-therapy 2025-07-15T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tdm-guided-ustekinumab-optimization-shows-superior-long-term-efficacy-in-crohn-s-disease-maintenance-therapy 2025-07-15T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-launches-adamunix-subsidiary-to-address-anti-drug-antibody-challenges-in-protein-therapeutics 2025-07-15T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoc4-launches-adamunix-subsidiary-to-address-anti-drug-antibody-challenges-in-protein-therapeutics 2025-07-15T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/elix-and-linc-launch-world-s-first-commercial-ai-drug-discovery-platform-using-federated-learning-from-16-pharmaceutical-companies 2025-07-15T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elix-and-linc-launch-world-s-first-commercial-ai-drug-discovery-platform-using-federated-learning-from-16-pharmaceutical-companies 2025-07-15T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/365mc-partners-with-raziel-therapeutics-to-advance-rzl-012-injectable-fat-reduction-treatment-in-south-korea 2025-07-15T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/365mc-partners-with-raziel-therapeutics-to-advance-rzl-012-injectable-fat-reduction-treatment-in-south-korea 2025-07-15T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-enables-kidney-transplant-patients-to-live-drug-free-for-over-two-years 2025-07-15T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-therapy-enables-kidney-transplant-patients-to-live-drug-free-for-over-two-years 2025-07-15T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-and-kailera-s-dual-glp-1-gip-obesity-drug-achieves-18-weight-loss-in-phase-3-trial 2025-07-15T17:23:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-and-kailera-s-dual-glp-1-gip-obesity-drug-achieves-18-weight-loss-in-phase-3-trial 2025-07-15T17:23:02+00:00 hourly 0.9 https://trial.medpath.com/news/fred-hutch-launches-national-vanguard-study-to-evaluate-multi-cancer-detection-blood-tests 2025-07-15T17:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fred-hutch-launches-national-vanguard-study-to-evaluate-multi-cancer-detection-blood-tests 2025-07-15T17:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-sh-110-oral-liquid-therapy-for-glioma-treatment 2025-07-15T17:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-sh-110-oral-liquid-therapy-for-glioma-treatment 2025-07-15T17:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiota-emerges-as-key-therapeutic-target-for-osteoporosis-through-novel-gut-bone-axis 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiota-emerges-as-key-therapeutic-target-for-osteoporosis-through-novel-gut-bone-axis 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-antibacterial-implant-materials-show-promise-against-bone-infections 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-antibacterial-implant-materials-show-promise-against-bone-infections 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-stromal-immunosuppressive-barrier-in-gastric-cancer-that-drives-treatment-resistance 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-stromal-immunosuppressive-barrier-in-gastric-cancer-that-drives-treatment-resistance 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-models-achieve-perfect-accuracy-in-early-childhood-diabetes-prediction-using-gene-expression-biomarkers 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-models-achieve-perfect-accuracy-in-early-childhood-diabetes-prediction-using-gene-expression-biomarkers 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/menin-inhibitors-market-poised-for-strong-growth-as-revuforj-becomes-first-fda-approved-drug-in-class 2025-07-15T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menin-inhibitors-market-poised-for-strong-growth-as-revuforj-becomes-first-fda-approved-drug-in-class 2025-07-15T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-danish-study-finds-no-link-between-aluminum-in-childhood-vaccines-and-chronic-diseases 2025-07-15T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-danish-study-finds-no-link-between-aluminum-in-childhood-vaccines-and-chronic-diseases 2025-07-15T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/quidelortho-and-buhlmann-launch-rapid-gastrointestinal-biomarker-assays-for-ibd-and-pancreatic-insufficiency-diagnosis 2025-07-15T13:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quidelortho-and-buhlmann-launch-rapid-gastrointestinal-biomarker-assays-for-ibd-and-pancreatic-insufficiency-diagnosis 2025-07-15T13:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/us-maternal-mortality-crisis-deepens-as-deaths-nearly-double-during-pandemic-commonwealth-fund-analysis-reveals 2025-07-15T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-maternal-mortality-crisis-deepens-as-deaths-nearly-double-during-pandemic-commonwealth-fund-analysis-reveals 2025-07-15T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-pharmaceuticals-partners-with-jcr-to-develop-enhanced-brain-delivery-therapy-for-alzheimer-s-disease 2025-07-15T13:22:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acumen-pharmaceuticals-partners-with-jcr-to-develop-enhanced-brain-delivery-therapy-for-alzheimer-s-disease 2025-07-15T13:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/4teen4-s-procizumab-shows-first-in-human-evidence-of-shock-reversal-in-terminally-ill-patients 2025-07-15T13:22:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4teen4-s-procizumab-shows-first-in-human-evidence-of-shock-reversal-in-terminally-ill-patients 2025-07-15T13:22:32+00:00 hourly 0.9 https://trial.medpath.com/news/oncomatryx-secures-eur12-5-million-eic-accelerator-funding-to-advance-novel-adc-platform-for-hard-to-treat-cancers 2025-07-15T13:21:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncomatryx-secures-eur12-5-million-eic-accelerator-funding-to-advance-novel-adc-platform-for-hard-to-treat-cancers 2025-07-15T13:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/follicular-lymphoma-market-poised-for-6-cagr-growth-through-2034-as-novel-therapies-advance 2025-07-15T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/follicular-lymphoma-market-poised-for-6-cagr-growth-through-2034-as-novel-therapies-advance 2025-07-15T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-to-hope-trial-shows-hope-reduces-liver-transplant-costs-by-28565-and-severe-rejection-rates 2025-07-15T12:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridge-to-hope-trial-shows-hope-reduces-liver-transplant-costs-by-28565-and-severe-rejection-rates 2025-07-15T12:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-treatment-pipeline-advances-with-extended-release-formulations-from-weekly-to-annual-dosing 2025-07-15T09:03:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-treatment-pipeline-advances-with-extended-release-formulations-from-weekly-to-annual-dosing 2025-07-15T09:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/korean-researchers-develop-precision-nanobody-therapy-for-lung-adenocarcinoma-with-90-tumor-reduction 2025-07-15T09:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-researchers-develop-precision-nanobody-therapy-for-lung-adenocarcinoma-with-90-tumor-reduction 2025-07-15T09:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biodynamics-episwitch-biomarkers-show-promise-in-pfizer-bladder-cancer-trial 2025-07-15T09:03:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biodynamics-episwitch-biomarkers-show-promise-in-pfizer-bladder-cancer-trial 2025-07-15T09:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/synendos-therapeutics-names-dr-george-garibaldi-as-cmo-to-lead-phase-2-development-of-novel-neuropsychiatric-therapy 2025-07-15T09:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synendos-therapeutics-names-dr-george-garibaldi-as-cmo-to-lead-phase-2-development-of-novel-neuropsychiatric-therapy 2025-07-15T09:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/mit-and-ucsb-researchers-develop-light-activated-platform-to-discover-broad-spectrum-antiviral-compounds 2025-07-15T09:02:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-and-ucsb-researchers-develop-light-activated-platform-to-discover-broad-spectrum-antiviral-compounds 2025-07-15T09:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/biophytis-partners-with-lynx-analytics-to-accelerate-ai-driven-drug-discovery-for-sarcopenia 2025-07-15T09:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biophytis-partners-with-lynx-analytics-to-accelerate-ai-driven-drug-discovery-for-sarcopenia 2025-07-15T09:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/usaid-funding-cuts-could-trigger-14-million-deaths-and-devastating-tb-crisis-by-2030 2025-07-15T08:54:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usaid-funding-cuts-could-trigger-14-million-deaths-and-devastating-tb-crisis-by-2030 2025-07-15T08:54:05+00:00 hourly 0.9 https://trial.medpath.com/news/heart-failure-pipeline-shows-strong-growth-with-75-therapies-in-development-across-70-companies 2025-07-15T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heart-failure-pipeline-shows-strong-growth-with-75-therapies-in-development-across-70-companies 2025-07-15T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/avacopan-demonstrates-superior-safety-profile-in-anca-associated-vasculitis-across-multiple-clinical-trials 2025-07-15T06:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacopan-demonstrates-superior-safety-profile-in-anca-associated-vasculitis-across-multiple-clinical-trials 2025-07-15T06:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-nppa-sets-retail-prices-for-71-essential-drug-formulations-including-cancer-and-diabetes-medications 2025-07-15T05:20:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-nppa-sets-retail-prices-for-71-essential-drug-formulations-including-cancer-and-diabetes-medications 2025-07-15T05:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-irrigation-rate-for-johnson-johnson-s-varipulse-pulsed-field-ablation-platform 2025-07-15T05:19:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-updated-irrigation-rate-for-johnson-johnson-s-varipulse-pulsed-field-ablation-platform 2025-07-15T05:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-profiling-transforms-aml-treatment-strategy-as-mrd-testing-guides-transplant-decisions 2025-07-15T05:19:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-profiling-transforms-aml-treatment-strategy-as-mrd-testing-guides-transplant-decisions 2025-07-15T05:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/telemedicine-transforms-oncology-care-with-86-of-cancer-specialists-calling-virtual-visits-essential 2025-07-15T03:54:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telemedicine-transforms-oncology-care-with-86-of-cancer-specialists-calling-virtual-visits-essential 2025-07-15T03:54:52+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-pharmacists-lead-biosimilar-integration-strategies-to-optimize-cancer-care-access-and-costs 2025-07-15T02:54:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-pharmacists-lead-biosimilar-integration-strategies-to-optimize-cancer-care-access-and-costs 2025-07-15T02:54:57+00:00 hourly 0.9 https://trial.medpath.com/news/anti-nausea-drug-aprepitant-shows-significant-survival-benefits-in-triple-negative-breast-cancer 2025-07-15T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-nausea-drug-aprepitant-shows-significant-survival-benefits-in-triple-negative-breast-cancer 2025-07-15T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/nostrum-laboratories-recalls-sucralfate-tablets-following-bankruptcy-and-operational-shutdown 2025-07-15T01:23:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nostrum-laboratories-recalls-sucralfate-tablets-following-bankruptcy-and-operational-shutdown 2025-07-15T01:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/60-degrees-pharmaceuticals-seeks-fda-mums-designation-for-first-oral-canine-babesiosis-treatment 2025-07-15T01:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/60-degrees-pharmaceuticals-seeks-fda-mums-designation-for-first-oral-canine-babesiosis-treatment 2025-07-15T01:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/unibar-corporation-secures-european-patent-for-capsiclear-eye-health-ingredient-targeting-glaucoma-treatment 2025-07-15T01:22:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unibar-corporation-secures-european-patent-for-capsiclear-eye-health-ingredient-targeting-glaucoma-treatment 2025-07-15T01:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-naturally-restore-testosterone-levels-in-men-with-obesity-and-type-2-diabetes 2025-07-15T01:21:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-naturally-restore-testosterone-levels-in-men-with-obesity-and-type-2-diabetes 2025-07-15T01:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/simulations-plus-invests-1-million-in-clinical-trial-technology-company-nurocor 2025-07-15T01:19:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simulations-plus-invests-1-million-in-clinical-trial-technology-company-nurocor 2025-07-15T01:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-drugs-remain-effective-despite-treatment-interruptions-when-combined-with-lifestyle-changes 2025-07-15T01:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-drugs-remain-effective-despite-treatment-interruptions-when-combined-with-lifestyle-changes 2025-07-15T01:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/whoop-challenges-fda-classification-of-blood-pressure-monitoring-feature-as-medical-device 2025-07-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whoop-challenges-fda-classification-of-blood-pressure-monitoring-feature-as-medical-device 2025-07-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/head-to-head-trial-compares-risankizumab-and-vedolizumab-in-treatment-naive-ulcerative-colitis-patients 2025-07-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/head-to-head-trial-compares-risankizumab-and-vedolizumab-in-treatment-naive-ulcerative-colitis-patients 2025-07-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bsa-encapsulated-morin-hydrate-nanoparticles-show-enhanced-anticancer-activity-against-colorectal-cancer 2025-07-14T21:24:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bsa-encapsulated-morin-hydrate-nanoparticles-show-enhanced-anticancer-activity-against-colorectal-cancer 2025-07-14T21:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/kaizen-biosciences-advances-pediatric-antibiotic-formulation-with-reduced-clavulanate-for-infants 2025-07-14T21:24:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaizen-biosciences-advances-pediatric-antibiotic-formulation-with-reduced-clavulanate-for-infants 2025-07-14T21:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/turn-therapeutics-initiates-first-clinical-trial-of-topical-il-36-inhibitor-gx-03-for-moderate-to-severe-eczema 2025-07-14T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turn-therapeutics-initiates-first-clinical-trial-of-topical-il-36-inhibitor-gx-03-for-moderate-to-severe-eczema 2025-07-14T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-s-primec-shows-33-reduction-in-als-disease-progression-in-phase-2b-trial 2025-07-14T21:22:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosense-s-primec-shows-33-reduction-in-als-disease-progression-in-phase-2b-trial 2025-07-14T21:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/uaeu-researcher-secures-four-patents-for-computational-drug-design-and-medical-device-innovations 2025-07-14T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uaeu-researcher-secures-four-patents-for-computational-drug-design-and-medical-device-innovations 2025-07-14T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/kenvue-ceo-thibaut-mongon-steps-down-as-consumer-health-company-undergoes-strategic-review 2025-07-14T17:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kenvue-ceo-thibaut-mongon-steps-down-as-consumer-health-company-undergoes-strategic-review 2025-07-14T17:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-reports-positive-interim-phase-3-results-for-ovaprene-hormone-free-monthly-contraceptive 2025-07-14T17:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dare-bioscience-reports-positive-interim-phase-3-results-for-ovaprene-hormone-free-monthly-contraceptive 2025-07-14T17:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-researchers-identify-gut-bacteria-strain-that-enhances-cancer-immunotherapy-effectiveness 2025-07-14T17:30:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-researchers-identify-gut-bacteria-strain-that-enhances-cancer-immunotherapy-effectiveness 2025-07-14T17:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/avalon-globocare-secures-hong-kong-patent-for-bispecific-car-t-and-car-nk-cell-technology 2025-07-14T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalon-globocare-secures-hong-kong-patent-for-bispecific-car-t-and-car-nk-cell-technology 2025-07-14T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-extends-evkeeza-approval-to-infants-as-young-as-6-months-for-rare-cholesterol-disorder 2025-07-14T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-extends-evkeeza-approval-to-infants-as-young-as-6-months-for-rare-cholesterol-disorder 2025-07-14T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/sonnet-biotherapeutics-pivots-to-cryptocurrency-with-888-million-hype-token-treasury-strategy 2025-07-14T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonnet-biotherapeutics-pivots-to-cryptocurrency-with-888-million-hype-token-treasury-strategy 2025-07-14T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-launches-deuruxolitinib-for-severe-alopecia-areata-in-us-market 2025-07-14T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-launches-deuruxolitinib-for-severe-alopecia-areata-in-us-market 2025-07-14T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/pci-pharma-services-secures-strategic-investment-to-expand-biotherapeutics-manufacturing-capabilities 2025-07-14T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pci-pharma-services-secures-strategic-investment-to-expand-biotherapeutics-manufacturing-capabilities 2025-07-14T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/endometriosis-pain-treatment-pipeline-shows-mixed-results-as-nhs-approves-first-daily-oral-therapy 2025-07-14T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endometriosis-pain-treatment-pipeline-shows-mixed-results-as-nhs-approves-first-daily-oral-therapy 2025-07-14T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/uniquity-bio-appoints-will-kane-as-ceo-to-lead-anti-tslp-therapy-through-phase-iii-development 2025-07-14T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniquity-bio-appoints-will-kane-as-ceo-to-lead-anti-tslp-therapy-through-phase-iii-development 2025-07-14T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-abandons-depression-drug-esmethadone-after-three-failed-phase-iii-trials 2025-07-14T17:26:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relmada-therapeutics-abandons-depression-drug-esmethadone-after-three-failed-phase-iii-trials 2025-07-14T17:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/essa-pharma-agrees-to-1-91-per-share-acquisition-by-xenotherapeutics-in-wind-down-transaction 2025-07-14T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essa-pharma-agrees-to-1-91-per-share-acquisition-by-xenotherapeutics-in-wind-down-transaction 2025-07-14T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/vivos-inc-submits-fda-application-for-radiogel-hydrogel-based-cancer-therapy 2025-07-14T17:25:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivos-inc-submits-fda-application-for-radiogel-hydrogel-based-cancer-therapy 2025-07-14T17:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-expands-generic-license-for-long-acting-hiv-treatment-to-133-countries 2025-07-14T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viiv-healthcare-expands-generic-license-for-long-acting-hiv-treatment-to-133-countries 2025-07-14T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/indiana-university-receives-11-3-million-nih-grant-to-advance-ship1-inhibitor-for-alzheimer-s-disease 2025-07-14T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indiana-university-receives-11-3-million-nih-grant-to-advance-ship1-inhibitor-for-alzheimer-s-disease 2025-07-14T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/waters-corporation-and-bd-announce-17-5-billion-merger-to-create-life-sciences-and-diagnostics-leader 2025-07-14T13:20:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waters-corporation-and-bd-announce-17-5-billion-merger-to-create-life-sciences-and-diagnostics-leader 2025-07-14T13:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/illimis-therapeutics-secures-42m-series-b-to-advance-gaia-platform-for-alzheimer-s-and-immune-disease-treatments 2025-07-14T13:19:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illimis-therapeutics-secures-42m-series-b-to-advance-gaia-platform-for-alzheimer-s-and-immune-disease-treatments 2025-07-14T13:19:20+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-raises-192m-in-oversubscribed-share-placement-to-advance-cancer-pipeline 2025-07-14T13:19:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-raises-192m-in-oversubscribed-share-placement-to-advance-cancer-pipeline 2025-07-14T13:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/ztz-bio-secures-fourth-global-big-pharma-partnership-for-long-acting-injectable-drug-development 2025-07-14T08:57:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ztz-bio-secures-fourth-global-big-pharma-partnership-for-long-acting-injectable-drug-development 2025-07-14T08:57:31+00:00 hourly 0.9 https://trial.medpath.com/news/cures-within-reach-launches-100000-grant-program-for-ai-driven-drug-repurposing-clinical-trials 2025-07-14T08:57:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cures-within-reach-launches-100000-grant-program-for-ai-driven-drug-repurposing-clinical-trials 2025-07-14T08:57:27+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-reports-75-response-rate-in-diffuse-large-b-cell-lymphoma-trial 2025-07-14T08:56:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-reports-75-response-rate-in-diffuse-large-b-cell-lymphoma-trial 2025-07-14T08:56:59+00:00 hourly 0.9 https://trial.medpath.com/news/antimalarial-drug-efficacy-remains-high-in-mozambique-and-liberia-despite-regional-resistance-concerns 2025-07-14T08:56:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antimalarial-drug-efficacy-remains-high-in-mozambique-and-liberia-despite-regional-resistance-concerns 2025-07-14T08:56:55+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-s-azer-cel-achieves-75-response-rate-in-phase-1b-trial-for-relapsed-dlbcl 2025-07-14T04:55:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-s-azer-cel-achieves-75-response-rate-in-phase-1b-trial-for-relapsed-dlbcl 2025-07-14T04:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-secures-european-patent-protection-for-gpc3-targeted-car-t-therapy-following-successful-defense-at-epo 2025-07-14T04:55:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-secures-european-patent-protection-for-gpc3-targeted-car-t-therapy-following-successful-defense-at-epo 2025-07-14T04:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/uk-and-vietnam-strike-ps250-million-pharmaceutical-trade-deal-to-accelerate-medicine-registration 2025-07-14T04:54:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-and-vietnam-strike-ps250-million-pharmaceutical-trade-deal-to-accelerate-medicine-registration 2025-07-14T04:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/genomill-health-s-bridge-capture-technology-matches-gold-standard-sensitivity-for-liquid-biopsy-in-metastatic-colorectal-cancer 2025-07-14T03:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomill-health-s-bridge-capture-technology-matches-gold-standard-sensitivity-for-liquid-biopsy-in-metastatic-colorectal-cancer 2025-07-14T03:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-developed-cancer-drug-prl3-zumab-shows-promise-for-treating-vision-loss-in-amd-and-diabetic-retinopathy 2025-07-14T01:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-developed-cancer-drug-prl3-zumab-shows-promise-for-treating-vision-loss-in-amd-and-diabetic-retinopathy 2025-07-14T01:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/implanted-vagus-nerve-stimulation-device-shows-promise-for-treatment-resistant-rheumatoid-arthritis 2025-07-13T21:17:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implanted-vagus-nerve-stimulation-device-shows-promise-for-treatment-resistant-rheumatoid-arthritis 2025-07-13T21:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/100-orange-juice-shows-no-blood-sugar-impact-in-type-2-diabetes-patients-clinical-trial-reveals 2025-07-13T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/100-orange-juice-shows-no-blood-sugar-impact-in-type-2-diabetes-patients-clinical-trial-reveals 2025-07-13T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/functional-nanomaterials-advance-photothermal-therapy-for-cancer-treatment 2025-07-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/functional-nanomaterials-advance-photothermal-therapy-for-cancer-treatment 2025-07-13T16:00:00+00:00 hourly 0.9